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Introduction 
1. THE TUMOR 
1.1 DEFINITION AND INTRODUCTION TO THE PATHOLOGY 
The term tumor or neoplasia refers to a new cell formation, almost always originating 
from a single cell of the organism that undergoes a sequence of genomic alterations 
transmitted to the progeny cells. The alterations in the genome that transform normal 
cells into neoplastic cells are usually structural (mutations) or, less frequently, functional 
(dysregulation, excessive or deficient gene transcription). These occur with a series of 
phenotypic effects consisting in both the appearance of abnormal functions, which are 
absent in normal cells, and in the loss or reduction of other functions, which are 
constantly present in the latter [1]. Alterations can affect both the germ line and the 
somatic line, even if most of the mutations or gene dysregulation phenomena, which give 
rise to cancer, are of the latter type [2]. Although most of the tumors have an epithelial 
origin, all cell types of the organism may undergo "neoplastic transformation" when they 
accumulate a number of damages to certain genes in their genome (proto-oncogenes, 
see chap. 1.3). Moreover, almost all cancers have a monoclonal origin, i.e. they are made 
up of a cell population that is the progeny of a single transformed cell, which has taken 
precedence over the others. Exceptions to this rule are represented by biclonal tumors 
(i.e. derived from two transformed cell types such as some forms of multiple myeloma) 
and tumors with polycenter origin in one single organ. 
The term tumor, which literally means swelling, was coined looking at the macroscopic 
appearance of most tumors, which have the shape of a raised mass in the anatomical 
region where they occur. 
The term neoplasia comes from the Greek νεοσ = new and πλασία = formation/growth, 
and literally means “new formation”. It is synonymous with the precedent term, but does 
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Introduction 
not concern the outward appearance of the mass; it is a definition from a cellular point of 
view, as neoplasia are actually made up by new formation cells. 
The term cancer derives from the Latin "cancer" (crab) and it was coined on the 
observation that in the malignant tumors peripheral neoplastic cells have offshoots, 
which surround normal cells and destroy them, like a crab grasping its prey with its claws. 
The term cancer was initially used referring to malignant epithelial tumors, but later it 
took a wider meaning indicating all forms of tumor. For that reason the branch of 
medicine which studies the etiopathogenic, diagnostic and therapeutic aspects of 
tumors is indistinctly referred to Cancer studies or Oncology (from the Greek ονxοσ = 
mass and λόγου = speech) [1]. 
 
1.2 MALIGNANT AND BENIGN TUMORS: THEIR CHARATTERISTICS 
AND DIFFERENCES 
 
Depending on their morphological characteristics, methods of growth and behavior 
towards neighboring tissues and the organism as a whole, tumors fall into two main 
groups: benign tumors and malignant tumors. 
Benign tumors are made of cells, which have morphological and functional characteristics 
that remain almost unaltered, although they are autonomously multiplicative. The 
autonomy of benign tumors is manifested not only by their inability to submit to the 
proliferation control mechanisms, but also by the ability of evading the homeostatic 
mechanisms, which regulate some of their functions [1]. They remain abnormal localized 
masses at the site of origin and, by definition, nor they do invade, i.e. they penetrate 
beyond the boundaries of adjacent tissues, or spread to distant sites. Deep tissue benign 
tumors are well delimited by a fibrous capsule, while those on the surface of tegumentary 
tissue grow outwards with the same growth polarity of the epithelial coating cells of skin 
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and mucous membranes. They grow more slowly than malignant tumors, but they may 
still cause damage to the neighboring tissues as a result of compression, although they 
are not invasive towards them. For example, an intracranial tumor of the meninges can 
lead to death a subject due to its compression on the brain [3]. Their development is 
termed expansive and they do not recur after surgical removal. 
Malignant tumors are characterized by morphologic atypia, which is more pronounced 
the more the tumor is undifferentiated. This atypia is manifested by alterations in shape 
and size of the cells (polymorphism) and/or cellular organelles, particularly the nucleus, 
which is frequently hyperchromic and in the mitotic phase. Unlike the benign tumor, 
which are characterized by expansive development, the malignant tumor is 
characterized by neoplastic invasion and more rapid growth. First, the neighboring 
tissues are infiltrated, then destroyed, so that in the course of proliferation they are 
replaced by the cells of the tumor itself. Invasiveness is not stopped by blood and 
lymphatic capillary and venule walls, which can be invaded and destroyed. The result is 
that cancer cells reach the bloodstream and/or lymphatic system, giving rise to the 
process known as metastasis, which involves the formation of secondary tumors, 
defined metastatic, far from the origin site. Metastasis is an extremely serious 
phenomenon for the body because it marks the transition from a local pathological 
manifestation to a wider one. Another feature of malignant tumors is the possibility of 
relapse, which is the recurrence of cancer in the same anatomical location and with the 
same characteristics as the one surgically removed. The relapse is probably due to the 
persistence of some infiltrating neoplastic cells in the tissues near the surgically removed 
tumor. Malignant tumors eventually give rise to cancer cachexia, i.e. a rapid and 
progressive deterioration of the body, which undergoes significant weight loss and 
serious phenomena of apathy and fatigue. Cachexia is caused by the production and 
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release of several toxic compounds by the neoplastic cells. Certainly the most efficient 
molecule in the genesis of cancer cachexia is a cytokine, the tumor necrosis factor 
(TNF=Tumor Necrosis Factor), also known as catechin, released in excess from neoplastic 
cells and also by tumor-bearing macrophages [1, 3].  
When cells undergo neoplastic transformation, they express surface antigens normally 
found only during fetal life; they may also express other signs of immaturity and exhibit 
both qualitative and quantitative chromosomal alterations, such as translations or 
amplifications of some gene sequences [4].  
 
1.3 PATHOGENESIS OF TUMORS 
Oncogenes are genomic sequences directly responsible for neoplastic transformation. By 
definition, oncogenes are all mutated genes that, in any way, with a gain in their 
function, contribute to the genesis and subsequent development of the tumor. They 
originate from proto-oncogenes, which are the very same genomic sequences that in 
normal cells controlling important functions for cell homeostasis. Some examples of 
classes of proto-oncogenes are genes involved in:  
  Regulation of the cell cycle; 
  cell immortalization;  
  inhibition of programmed cell death;  
  tumor angiogenesis; 
  formation of the stroma; 
  tumor invasiveness; 
  metastasis;  
  control processes of cell adhesion;  
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  accumulation of mutations. 
The transformation from proto-oncogenes to oncogenes occurs as a consequence of 
mutation, gene amplification/rearrangement or transcription dysregulation; oncogenes 
acquire the power to stably transform the normal cell in which they are contained into a 
neoplastic one. In comparison to related proto-oncogenes from which they derive, 
oncogenes encode either for an excess of the product (in the case of gene amplification 
or dysregulation) or for an altered product in its structure, which performs an excessive 
function (in case of mutation). Mutations, which convert proto-oncogenes into 
oncogenes, are always activating mutations. As the mutation, or amplification, of only 
one single copy of the gene is necessary to determine the effects of excess product, it is 
said that oncogenes behave as dominant genes. By the way, proto-oncogenes encode 
products responsible for the advancement of cells cycle (e.g. growth factors, receptors for 
growth factors, transcription factors, cyclins, CDK etc.).  
All animal cells also possess another category of genes, which assumes a position of 
enormous importance in all phases of carcinogenetic process, the so-called tumor 
suppressor (oncosuppressor) or anti-oncogenes. At the level of these specific DNA 
sequences, inactivating mutations such as gene deletions or gene silencing phenomena 
occur - the latter as a consequence of hypermethylation phenomena - that either prevent 
the codification or determine the functional inactivation of the product. They are defined 
as tumor suppressor genes because, under physiological conditions, they code for 
products called anti-oncoproteines which areengaged in a series of inhibitory functions 
contrasting those carried out by proteins encoded by oncogenes like, for example, 
inhibition of cell cycle progression until it stops completely (e.g. Rb, p-53, NF-1, BRCA-1, 
BRCA-2, bcl2). For few notable exceptions, tumor suppressor genes behave as recessive 
genes, so it is necessary that both allelic copies of the same gene must be deleted or 
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mutated or silenced in order to determine a loss of their function. The exception to this 
rule is when the products of tumor suppressor genes are not active in monomeric, but in 
omotetrameric form, so it is sufficient that one of the molecules, which constitute the 
composition of the omotetramer, is altered to lose its physiological function. This is the 
case of the protein encoded by the anti-oncogene Tp53 that is seen to be mutated in as 
much as 75% of human tumors. In addition, many tumor suppressor genes undergo 
mutations in their germ line cells, becoming responsible for the appearance of hereditary 
substrate tumors [1].  
According to several results from research on experimental carcinogenesis induced by 
chemical and physical agents, widely confirmed by clinical observations, a number of 
evolutionary stages in the process of carcinogenesis have been identified, which together 
can be traced back to three:  
1) Initiation, during which one or more mutations, or sometimes one or more 
phenomena of dysregulated gene expression, or both together, transform a 
normal somatic cell into a latent neoplastic one, that is, a tumor cell still unable 
to replicate autonomously.  
2) Promotion, when the “primed” cell begins to multiply and form a clone of cells 
carrying its genomic alterations, due to either further genomic damage in 
addition to that already present, or proliferative stimuli. The clone becomes 
clinically manifest when it reaches a certain mass.  
3) Progression, consisting in the subsequent accumulation of mutations in the 
genome of some cells of the neoplastic population (such as, for example, those 
responsible for the occurrence of invasive or metastatic phenotypes), which can 
gain the upper hand in the reproduction through selective phenomena, and  form 
quantitatively dominant sub-clones which in turn may further modify the 
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biological behavior of the tumor. For this reason, once formed, the tumor is not 
a static, but a dynamic entity, because its cell population, albeit derived from a 
single transformed cell, is not homogeneous (i.e. not made up of cells 
morphologically and functionally identical among themselves). They present 
several levels of heterogeneity with the result that the percentage of 
considerably aggressive cells in the tumor increases [1].  
In this heterogeneous neoplasm, there is experimental evidence, which shows the 
presence of a sub-population of cells, the so-called stem cells, characterized by their 
abnormal tendency to proliferate and form tumors, which grow locally and compress 
or invade adjacent normal tissues [4]. The accumulation of additional genomic 
damage in some cells of the tumor cell population is due to the fact that neither the 
genes which, via their product, code for proteins responsible for metabolism and 
DNA replication, nor those that code for enzymes involved in repairing damage 
caused to this macromolecule are spared. This is the phenomenon called genomic 
fragility. These genomic damages gradually accumulate, because of the absence of 
their repair. It is not yet clear why the phenomenon of genomic fragility does not 
generally arise in benign tumors, and the fact that its appearance determines their 
transformation in malignancies requires more evidence [1]. 
Therefore, what is altered is the normal cell cycle (Figure 1), which is defined as the 
set of sequential phenomena culminating in mitosis which occur with overlapping 
mode in all somatic cells, except for the perennial ones (neurons, myocytes...). These, 
under normal conditions, do not ever multiply.  
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Figure 1. The cell cycle 
 
The multiplicative independence of tumor cells, which is manifested in the continuous 
succession of replicative cycles, results from alterations undergone by proto-oncogenes 
and tumor suppressor genes, which physiologically oversee the smooth functioning of 
cell multiplication.  
Tumor growth does not depend on the speed with which the cancer cells replicate, but 
on the greater number of cells, which multiply together, and on their lower number in 
multiplicative rest or undergoing programmed cell death (or apoptosis). 
As a consequence, the surviving cells continue to multiply. 
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2. THE CAUSES OF TUMORS 
Rise, geographical distribution and behavior of various forms of cancer depend on several 
factors that include:  
 intrinsic factors, which are inherent in the body. They are represented by gender, 
age, hormonal imbalances, race and genetic predisposition to mutations, and all 
of them are transmitted from parents to offspring;  
 extrinsic factors, i.e. exposure to environmental carcinogens.  
Among these various factors, environmental exposure is probably the most important 
cause of tumor formation. The main environmental factors implicated in carcinogenesis 
are: physical agents, chemicals, and oncogenic viruses. 
 
2.1 CARCINOGENESIS BY PHYSICAL AGENTS  
Physical agents considered to be carcinogenic are: ultraviolet radiation, ionizing radiation 
and foreign bodies. 
2.1.1 ULTRAVIOLET RADIATION 
 
Many epidemiological investigations have shown that ultraviolet radiations from 
sunlight or artificial sources play an important role in the etio-pathogenesis of some skin 
tumors. Exposure of the body to these radiations can produce lesions limited to 
superficial tissues, which undergo an inflammatory erythematic reaction or blistering. 
These effects are amplified when fluorescent substances are present on the skin: they 
absorb radiation at a certain wavelength and emit it at a longer one, together with free 
radicals, which are formed during the reaction. This amplification is the so-called photo-
dynamic effect, which is carried out by both endogenous compounds, such as porphyrins, 
and compounds with which the skin comes into contact, including drugs like quinine, and 
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some perfumes like the essence of bergamot. When exposure is repeated over time, for 
example due to occupational reasons, there is persistent tanning because the synthesis 
of melanin in the melanocytes is persistently stimulated. The epidermal cells undergo 
hyperplasia and keratosis, i.e. thickening of the stratum corneum. The lighter the color of 
the skin, the higher its sensitivity is going to be. In fact, melanin exerts a protective effect 
because it absorbs UV radiation, so that tanning is considered a form of adaptation to 
particular environmental conditions.  
UV radiation, known also as exciting, is that portion of the electromagnetic spectrum 
with wavelengths between 100 and 400 nm and is divided into three bands of different 
wavelength ranges: UV-A = 400-315 nm, UV-B = 315-280 nm and UV-C = 280-100 nm. A 
carcinogenic effect has been demonstrated only for wavelengths between 290 and 320 
nm. Prolonged exposure to radiation with wavelengths between 250 and 300 nm, which 
are preferentially absorbed by nucleic acids and proteins, is also a powerful risk factor for 
the onset of basocellular and spinocellular epitheliomas and melanomas in those areas 
more exposed to radiation, such as the face and hands. Their oncogenic power is related 
to their ability to induce mutations in the DNA of target cells and is expressed mainly in 
the formation of dimers of pyrimidine bases (in particular thymine and cytosine), which 
stably deform DNA. Biological results of this mutation are: enzyme inactivation, cell 
division alterations, mutagenesis, cell death (necrosis) and cancer. The body has defense 
mechanisms against such damages. Actually, in normal subjects the sites of altered DNA 
are recognized and removed by specialized enzymatic systems, and are replaced by 
newly synthesized DNA. But when UV exposure is persistent over the years, repair 
mechanisms do not always eliminate all damages. As a direct consequence of lack of 
repair, the damage may accumulate, cause neoplastic transformation and be 
transmitted to the cell progeny. Moreover, repair cannot be effected if damage affects 
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homologous sites in the two strands of the DNA double helix; to replace the affected 
portion, DNA is synthesized from DNA-Polymerase which uses the homologous site as 
an intact template.  
Patients with hereditary diseases such as Xeroderma Pigmentosum, which cause defects 
in the DNA repair mechanisms, have high risk of developing tumors in body's parts 
exposed to sunlight [1]. 
2.1.2 IONIZING RADIATIONS 
 
The earliest indications of pathogenic effects of ionizing radiation were a consequence 
of the spread of X-rays for diagnostic and therapeutic purposes; radiologists and 
radiology lab technicians, unaware of the risks they ran, were exposed to radiation during 
their work and patients were generally subjected to high dosages. Then, experience has 
led to the development of suitable protective equipment for radiology laboratory 
workers.  
Further information concerning the harmful effects of ionizing radiation came from the 
observation of the consequences of long-term occupational exposure to natural 
radiations. It is an important risk factor for the insurgence of solid cancers, especially for 
the lung, and for leukemia in workers in Uranium mines. 
Finally, the third -and most tragic- experience was gained from survivors of the atomic 
bomb explosions in Hiroshima and Nagasaki, and those of accidents in nuclear power 
plants.  
The toxic mechanism underlying ionizing radiation carcinogenesis is: 
1. Direct toxic action following absorption of radiation (which consists of primary, and in 
some cases secondary, ionization phenomena) by those cellular constituents with 
higher molecular weight than others. The DNA is the first, ranging from breakage of 
one or both filaments to distortion and breakage of bases and formation of cross-
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links, which cause cell death or mutations. Proteins too undergo alterations in their 
primary, secondary and tertiary structures leading to disruption or loss of function. 
Lead shielding, which absorbs radiation, can prevent such direct action.  
2. Indirect toxic action triggered by the transfer of energy to water, the most plentiful 
constituent in cells, which undergoes ionization phenomena. From this process free 
radicals are formed, some of which are oxidants and others reducing agents (H2O+, 
OH-, H+…), and all molecules that can undergo oxidation-reduction phenomena are 
subject to them - especially lipids that are peroxidized - with additional formation of 
free radicals, which amplify the peroxidative reaction. The body is able to defend itself 
from oxidative damage by enzymes such as superoxide dismutase (SOD), which acts 
on O2-, and catalase, which decomposes H2O2 in H2O and O2, the latter fairly 
unresponsive. Antioxidant or reducing agents (e.g. Vitamins A, C and E, reduced 
glutathione and cysteine etc.) prevent the indirect action of ionizing radiation.  
As already observed, there are various pathological effects, and their seriousness is 
always directly correlated to the dose of radiation absorbed. 
2.1.3 FOREIGN BODIES 
 
Numerous experiments on rodents have shown that some inert materials are able to 
induce various types of sarcomas, following their implantation within the body (in 
subcutaneous tissue). Among these, there are plastic films and metal foil (e.g. gold foil), 
various fibers of organic and inorganic material, carbon discs and many others. 
For what concerns carcinogenesis it must be considered the size, the smoothness of the 
surface and the duration of the implant: for example, the incidence of tumor occurrence 
decreases, until it disappears altogether, if perforated plates are implanted (and the 
decrease is proportional to the number and diameter of the perforations) and it increases 
with enlarged surface area of the lamina. There is no relationship between the chemical 
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nature of the lamina and the onset of tumors: the same material, if implanted 
subcutaneously in equal amounts, but in form of powder, is free of oncogenic properties. 
These tumors are species-specific: for example, rats and mice are highly susceptible to 
carcinogenesis from foreign bodies, while humans seem to be much more resistant in 
this sense.  
It has not yet been fully established whether the tumors associated with exposure to 
asbestos (see chap.2.3.1) should be considered tumors induced by physical or by non-
genotoxic chemical agents [1]. 
 
2.2 VIRAL CARCINOGENESIS  
Initially oncogenic viruses were deemed responsible for the appearance of several types 
of tumors only in animals, but now it has been recognized that there are some viruses 
also involved in the genesis of human cancers. 
Oncogenic viruses are divided into two large groups: those in which the genome consists 
of DNA (OncoDNA virus) and those in which the genome is composed of RNA (Retrovirus).  
Viral carcinogenesis is a "one-shot" process; in other words, the penetration of one single 
virion in the cell will lead to a neoplastic transformation. Furthermore, it is constantly 
associated with integration of viral genome – either entirety or in part - into the cellular 
genome and its functional persistence there. This phenomenon is known as insertional 
mutagenesis. 
ONCODNAVIRUS 
Cells respond in two different ways to infections caused by DNA oncogenic virus:  
 permissive cells replicate the virus and suffer its cytopathogenic effect, by 
consequence of which they die when releasing newly synthesized virions. 
Accordingly, they never become cancer cells. 
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 non-permissive cells do not replicate the infecting virus; they undergo neoplastic 
transformation after the incorporation of all, or part of  the viral genome into theirs. 
In particular, the regulatory (promoter or enhancer) sequences of viral genes are 
positioned in proximity to cell proto-oncogenes, which are activated accordingly. 
Viral genes, which are considered true oncogenes, encode for proteins, which act at 
the level of the cell membrane and cytoplasm, especially the nucleus, stimulating the 
processes of cell proliferation. Some of them are able to activate products of proto-
oncogenes, making them functionally similar to those encoded by the corresponding 
oncogenes; while others inactivate the products of tumor suppressor genes, 
especially p53 and p105RB.   
Ultimately, the process of insertional mutagenesis is the cause of mutations in which 
oncogenes and tumor suppressor genes are involved. These are, respectively, activated 
or inhibited by proteins, which are encoded by viral genes.  
Table 1 reports DNA virus oncogenes most frequently involved in tumor genesis in 
humans.   
RETROVIRUS 
Retrovirus are so called because there is in the genome a gene (pol), coding for the viral 
enzyme reverse transcriptase. After penetration within the cell, virus will transform the 
RNA of viral genome into double helix DNA, which is incorporated into cellular genome 
by the integrase enzyme. Retroviruses are causative agents of several types of cancer in 
many animal species.  
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Table 1 [1]. DNA tumor viruses 
 
* Especially strains 16 and 18.  
** The insurgence of this tumor also follows infection induced by another hepatotropic virus belonging to 
the category of viruses with RNA genome, the hepatitis C virus (HCV). 
 
They are divided into:  
 acute transforming - induce the rapid appearance of tumors in animals and neoplastic 
transformation of normal cells in culture. They are carriers of oncogenes. 
 slow transforming, devoid of oncogenes. These induce the onset of tumors in animals 
after a long incubation period and are not capable of inducing neoplastic 
transformations of normal cells in culture.  
In acute transforming retrovirus-infected cells, neoplastic transformation is triggered by 
incorporation into cellular genome of viral oncogene, followed by additional genomic 
alterations. The neoplastic transformation induced by slow transforming retrovirus is 
essentially linked to incorporation of their genome in the vicinity of a proto oncogene, 
which is activated by regulatory sequences of viral gene. In either case, in contrast to 
what happens for DNA tumor viruses, viral replication can be carried out by the 
neoplastic cells. Table 2 shows DNA tumor viruses most frequently involved in the 
genesis of tumors in humans [1]. 
 
 
Virus DNA Associated Tumors 
Epstein-Barr Virus (EBV) Burkitt’s Lymphoma 
Carcinoma of nose/pharynx  
Lymphocyte lymphoma  
Type B Lymphoma  
Human Papilloma virus (HPV)* Ano-genital Carcinomas  
Hepatitis B Virus (HBV) Liver Carcinoma ** 
Kaposi’s Herpes Virus or  Human Herpes virus 8 
(HHV-8) 
Kaposi’s Sarcoma  
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Table 2 [1]. RNA tumor viruses 
 
 
 
 
* retroviruses HIV-1 and HIV-2, the causative agents of AIDS  (Acquired Immune Deficiency Syndrome),  are 
not considered oncogenic viruses, but they do cause a state of severe immunodeficiency and facilitate the 
emergence of tumors in infected individuals, defined as  opportunistic like the infections which they are 
subject to.  
 
2.3 CHEMICAL CARCINOGENESIS  
A key event for connecting the onset of cancer to exposure to chemicals was in 1775, 
when Sir Percival Pott, a British surgeon, noticed considerable increasing in the incidence 
of cancer of the scrotum among those people who had been chimney sweeps in their 
youth. In 1873, further observations were advanced on the incidence of skin cancer 
among laborers working with tar.  
However, the actual study of chemical carcinogenesis was born in 1915, when the first 
controlled experiment of carcinogenesis in animals was published by two Japanese 
researchers, Yamagiwa and Ichikawa. They managed to cause the appearance of 
cutaneous squamous cell carcinomas in rabbits by painting repeatedly particular areas of 
their bodies with small doses of tar day by day. Repetitive treatment of the skin with tar 
attempted to reproduce the same conditions as those observed in previous years, which, 
as mentioned, had shown a cause and effect relationship between prolonged exposure 
to tar due to occupational reasons and the appearance of skin cancers after many years. 
In further research on chemical carcinogenesis with different species of animals, 
especially mice, many other chemical compounds were examined, using numerous other 
routes for administration and improving the study method of neoplastic 
Virus a RNA Tumori associati 
HTLV-1 e HTLV-2 (= Human T cell Leukemia 
Virus) 
T-cell leukemia  
Lymphomas (various) 
HIV-1 e HIV-2* Lymphomas 
Kaposi Sarcoma  
Hepatitis C Virus (HCV) HCC 
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transformations. It was discovered that carcinogenic (literally generators of cancer) 
chemicals were active not only in causing the insurgence of tumors in animals, but were 
also able to produce neoplastic transformation of cells in culture. Thanks to these 
investigations, it was proved that, with the exception of arsenic derivatives, all the 
chemical compounds suspected of causing the appearance of tumors in those who, due 
to professional reasons, had been in contact with them for many years, were 
carcinogenic also for experimental animals. From this result it was concluded that all 
chemical compounds that are oncogenic for experimental animals must be considered 
(albeit potentially) oncogenic for humans too. This in turn, gave rise to the general rule 
of experimenting all the newly-synthesized chemical compounds, presumed to be for 
human use, for evidence of carcinogenesis. 
By definition chemical carcinogens are "those agents whose administration induces the 
appearance of tumors in experimental animals which, in the absence of such 
administration, remain free of malignancies" [1, 2].  
Almost all of the chemical carcinogens analyzed are genotoxic, i.e. they damage DNA, 
leading to the appearance of mutations. Of course, this does not mean that all mutagens 
are to be considered carcinogenic. Actually, not all mutations are related to neoplastic 
transformation. There are few non-genotoxic chemical carcinogens: their carcinogenic 
effect is related to epigenetic phenomena, namely the functional dysregulation of genes, 
without structural alterations.  
Every chemical carcinogen induces appearance of tumor in experimental animals only 
when administered at a particular dosage (threshold dose) that appears to be well-
defined for each compound examined. Since the administration in a single shot of many 
compounds in a quantity corresponding to the threshold dose may, in many cases, cause 
the death of animals due to acute toxicity, it became necessary to split the threshold dose 
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into smaller ones, consequently prolonging the duration in time of the experiment. For 
this reason, chemical carcinogens were defined as summationally toxic, meaning that 
repeated administration of a carcinogen over time leads to the appearance of tumor in 
the animal undergoing treatment, when this has received a quantity exactly 
corresponding to the threshold dose.  
This led to the conclusion that chemical carcinogenesis is a multistep process, namely that 
takes place in several stages, each of which causes the mutation of certain genes. When 
these data are reviewed from the molecular biology point of view, it becomes clear that 
prolonged administration of carcinogen over time, until the threshold dose is reached, 
will probabilistically give rise to those mutations in proto-oncogenes and tumor 
suppressor genes, which underlie the appearance of tumors. Administering carcinogen 
to animal at dose below the threshold does not cause the appearance of tumors. 
However, tumors do appear if the animal subsequently receives doses of the remaining 
amount of carcinogen until the threshold dose is reached. Some chemical compounds, 
not carcinogenic by themselves, cause the appearance of tumors only when 
administered to animals, which was previously treated with carcinogen, even at a 
considerably lower dosage than that constituting the threshold dose. These compounds 
are called cancer-promoting agents or co-carcinogens. They do not act on DNA, but 
essentially favor the processes of cell replication. The process of co-carcinogenesis is 
always unidirectional, so that administration of the subliminal carcinogen dose must 
always precede the promoting agent's one.  
By analyzing a wide number of results obtained experimentally through the 
administration of a subliminal carcinogenic dose to animals followed by a promoting 
agent's one, Berenblum formulated the theory of multiphase carcinogenesis. He 
distinguished the stages of initiation, promotion and progression [1], discussed in chapter 
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1.3. The distinction between initiators and promoters is important: the initiators - at least 
when they are in small doses - do not produce cancer, although they usually produce 
mutations. Without a secondary stimulus, transformation into malignant cells is highly 
unlikely. However, if these cells are subsequently exposed to a promoter, the malignant 
phenotype arises. In absence of initiators, promoters are usually neither genotoxic nor 
mutagenic. Among the most important promoters are 12-O-tetradecanoil-13-acetate 
(TPA, Figure 2), organochlorine pesticides and many hormones (such as estrogens) [2, 6].                        
   
 
 
 
 
Figure 2. TPA 
 
Chemical carcinogens are divided into two broad categories:  
1. Direct Carcinogens: act directly on the DNA. They do not require the formation 
of metabolic derivatives; 
2. Procarcinogens or indirect carcinogens: these are not carcinogenic as such, but 
some of their products, resulting from enzymatic reactions, are. Metabolic 
activation of pro-carcinogens occurs in microsomes via a highly complex enzyme 
system, which causes their oxidation with formation of derivatives with greater 
electrophilicity, i.e. the ability to interact with nucleophilic compounds like the 
DNA (intermediate and terminal carcinogens).  
Both direct carcinogens and procarcinogens are genotoxic and carcinogenic initiator 
agents.  
A third category may be added to these two, the Non-genotoxic or Epigenetic 
Carcinogens [1]. 
H3C O
O
O
H3C
H
HO
OH
HO
CH3
CH3
OCH3H3C
H
H
 25 
 
Introduction 
2.3.1 DIRECT CARCINOGENS  
Inorganic compounds  
A variety of metals or metal compounds can induce many occupational cancers, although 
their mechanism of action is still unknown. Among these: arsenic, iron, chromium, nickel, 
cobalt and cadmium. One possible explanation, which accounts for their carcinogenicity, 
states that they are able to interact with the bases or the phosphate groups of DNA due 
to their nature of divalent cations and electrophiles.   
Among the best-documented inorganic compounds, recognized as responsible for 
professional oncogenic diseases in humans, there are the tri- and pentavalent derivatives 
of arsenic: prolonged exposure to those compounds has been proved to be responsible 
for the onset of skin tumors by direct contact and lung tumors following inhalation [7].  
Acetylating and alkylating compounds 
The common feature of alkylating agents is that they yield alkyl groups to nucleophilic 
sites of cellular macromolecules, especially in functional groups containing nitrogen, 
oxygen and sulfur, thus establishing covalent bonds with them. Although these agents 
can potentially damage all cellular macromolecules, their biological effects are attributed 
to their ability to affect DNA, particularly at the O6 and N7 positions of guanine, adenine 
and the O3 oxygen atoms in the phosphate group [2]. They do not require metabolic 
activation; however, other compounds (e.g. nitrosamines and vinyl chloride) are 
metabolically activated to alkylating compounds, or achieve this capacity, through 
spontaneous chemical degradation (e.g. Temozolomide).   
There are numerous alkylating agents that can be classified as monofunctional and 
bifunctional, according to their mode of interaction with DNA. Monofunctional 
compounds induce the alkylation of specific DNA bases, while bifunctional compounds 
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create intra and/or intermolecular cross-link interactions between the chains of DNA, 
usually through the alkylation of N7 in guanines of anti-parallel helixes. The alkylating 
agents with greater toxicity are usually precisely the latter.  
Examples of alkylating agents are β-propiolactone, dimethyl sulfate, di-epoxy butane, 
cyclophosphamide and other anticancer drugs [5, 7]. 
Certain acetylating agents (e.g. 1-acetylimidazole) are considered carcinogenic 
compounds, although they are "weak" carcinogens [7]. 
2.3.2 INDIRECT CARCINOGENS 
Polycyclic aromatic hydrocarbons (PAH)  
Particularly important in the field of experimental, professional and even environmental 
oncology, are polycyclic aromatic hydrocarbons, so-called because they consist of 
several joined rings and some of them have a characteristic pleasant smell. However, 
most polycyclic hydrocarbons are formed during the combustion of organic materials, 
generally at high temperatures. Actually, cyclization rarely occurs at temperatures below 
600 ° C and most of them are generated between 600-950 ° C, while above 1000 ° C they 
undergo the phenomenon of pyrolysis, i.e. thermolytic degradation of their constituent 
rings. Since they are fat-soluble molecules, they easily pass through cell membranes.  
Polycyclic aromatic hydrocarbons are divided into homocyclic and heterocyclic 
compounds; the former consist of benzene rings only, while the latter contain at least 
one other non-benzene ring in their structure. They are also divided into substituted and 
non-substituted, depending on whether instead of one, or more, hydrogen atoms there 
are, or not, one or more (usually methyl or ethyl) chemical groups. Generally, 
carcinogenic PHAs contain several benzene rings, usually from three to no more than six; 
in fact, those consisting of more than six conjugated rings exert no oncogenic activity. 
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However, it also depends on the substitution of certain chemical groups in the molecule; 
usually, methylation enhances oncogenic activity and sometimes can give rise to it in no-
carcinogenic compounds. Moreover, the methyl groups must be located in a suitable 
position.  
PHAs are homocyclic derivatives of phenanthrene, anthracene, pyrene and chrysene. 
Contrary to these molecules, which are not carcinogenic, their methylated derivatives 
and those obtained by addition of more benzene rings are. Examples of non-methylated 
PHAs are 1:2-benz(a)anthracene, benzo(c)phenanthrene, benzo(a)pyrene and 
dibenz(a,c)anthracene (Figure 3). Among the methylated homocyclic PHAs, there are, for 
example, 9,10-dimethylanthracene and 1, 4-dimethylphenanthrene (Figure 3). 
 
 
            
                  1:2-benz(a)anthracene                                             Benzo(c)phenanthrene  
                  
 
 
                         Benzo(a)pyrene                                                   Dibenz(a,c)anthracene 
  
  
          
                9,10-dimethylanthracene                                   1,4-dimethylphenanthrene 
Figure 3. Derivatives of phenanthrene, anthracene, pyrene and chrysene 
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The derivatives of fluorene, fluorantrene and acridin are heterocyclic PHAs; starting 
molecules are not carcinogenic, while their methylated derivatives or those obtained by 
addition of more benzene rings e.g. benzo(j)fluoranthrene and benzo(k)fluoranthrene 
(Figure 4) are.   
 
 
 
 
Benzo(j)fluoranthrene Benzo(k)fluoranthrene
Figure 4. Derivatives of fluorene, fluorantrene and acridin 
Experimental investigations demonstrated that aromatic homocyclic hydrocarbons 
exerted more carcinogenic activity than heterocyclic ones. They are found in cigarette 
smoke, and are mainly present in the air of urban areas because such compounds are 
formed directly by fuel burned for household heating and industrial purposes. In humans, 
tumors induced by these substances affect skin, respiratory system and gastro-intestinal 
tract.  
PAH are procancerogens and become carcinogenic after metabolic activation, which 
may take place through one or more stages; in the latter case, the formation of final 
carcinogen is preceded by the synthesis of one or more intermediate compounds, each 
with its own reactivity. The active compounds are generally epoxides, diolepoxides, and 
diols which, being unstable and strongly electrophilic, bind to DNA nucleophilic sites, 
proteins and lipids [7, 8]. 
Aromatic Amines  
Aromatic amines are pro-cancerogenous compounds and derivatives of aniline, which is 
the simplest aromatic amine and is devoid of oncogenic activity, although equipped with 
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certain degree of toxicity. Many of its derivatives, mostly obtained by condensation - 
therefore consisting of two condensed benzene rings having one or more aminic groups 
- were the subject of in-depth studies in order to identify what makes them carcinogenic. 
The most significant products are diphenyldiamine (benzidine), the 2-naphthylamine (or β-
naphthylamine, 4-aminodiphenyl (Figure 5), all of which are intermediates used for the 
synthesis of dyes and explosives. 
All aromatic amines have the same carcinogenic mechanism of action, consisting in 
metabolic activation of pro-cancerogens into carcinogens which are the real causes of 
cancer. For example, 2-naphthylamine, after hepatic metabolism, is activated to the 
definitive carcinogen 1-hydroxy-2-aminonaphthol (Figure 5), responsible for the onset of 
bladder tumors. Interestingly, α-naphthylamine (Figure 5) is not a carcinogen. It was 
suggested that in the process of metabolic activation, since the position 1 of the ring is 
already occupied by an amino group, the hydroxylation reaction, responsible for the 
formation of a carcinogenic compound, cannot take place in this position. The reason 
why oxidation in para, rather than ortho, does not lead to activation is unknown.  
 
                       4-aminodiphenyl                                             Diphenyldiamine (benzidine)
 
 
2-naphthylamine (β-naphthylamine)         1-hydroxy-2-aminonaphthol 
                                                                       
           
           
 
1-naphthylamine (α-naphthylamine) 
Figure 5. Most significant pro-cancerogenous aromatic amines 
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Another group of aromatic amines, originating from diamino-diphenyl-methane, is 
involved not only in experimental, but also in professional carcinogenesis. The most 
thoroughly studied compounds are 3,3'-dimethyl-diamino-diphenyl-methane , also called 
Magenta Green, 3,3'-dichloro-diamino-diphenyl-methane , known as MOCA, and 
auramine (Figure 6). 
 
 
Magenta Green                                                            MOCA 
 
 
Auramine 
Figure 6. Another group of pro-cancerogenous aromatic amines 
 
The third group of pro-carcinogenic aromatic amines is represented by the derivatives of 
fluorene, especially those from 2-acetyl-aminofluorene (Figure 7). This is a very potent 
insecticide that was patented in 1940, never permitted for production on large-scale 
because of its strong pro-carcinogenic activity in many animal species, issued during 
long- and short-term toxicity tests to which it was subjected. These derivatives too 
display pro-carcinogen activity, becoming definitive carcinogens only after metabolic 
activation. However, in this case activation does not occur by N-hydroxylation, but by N-
esterification. The first of these compounds to be studied was N-acetyl-2-aminofluorene 
which forms adducts with both guanosine and methionine. Among these compounds, 
the sulfuric ester of N-hydroxyamino-fluorene (Figure 7) seems to be the most active [8]. 
 
 
CN N
H3C
H3C
CH3
CH3NH
CH3
NH2
H3C
H2N
Cl
NH2
Cl
H2N
 31 
 
Introduction 
 
 
 
                 Acetyl-2-aminofluorene                              Sulfuric ester of N-hydroxyamino 
                                                                                                                          fluorene 
                         
Figure 7.  Pro-carcinogenic aromatic amines derivatives of fluorene 
Azo-compounds 
Azo-compounds are made up of molecules characterized by the presence of benzene 
rings containing at least one amino group linked by two nitrogen atoms between which 
there is a double bond. Experimental research about their oncogenic activity were very 
intense as a large number of them are food dyes for which carcinogenicity in animals has 
been demonstrated. Among these are orthoaminoazotoluolo, better known as scarlet red 
and dimethyl-amino-azobenzene (DAB), (Figure 8), commonly known as butter yellow. 
 
                     
 
 
Scarlet red                                                      DAB
Figure 8. Azo-compounds 
 
Both DAB and other compounds were found to have oncogenic power depending on 
certain properties of the molecule, for example: 
 the trivalency of the two nitrogen atoms joined by a double bond (-N=N-) because 
when this bond is reduced (-NH-NH-) the carcinogenic activity of this compound 
disappears; 
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 the presence of methyl groups in certain positions in the structure like 
monomethyl-amino-azobenzene (MAB) that is less active than dimethyl-amino-
azobenzene (DAB) which in turn is less active than its 3'-methyl derivative. On the 
other hand, the addition of methyl groups in other positions may determine the 
reduction or even disappearance of oncogenic powers;  
  the substituents of the amino group. Only if they are methyl and/or ethyl, the 
molecule will be equipped with oncogenic capacity; on the contrary, if substituents 
are more complex, compounds are non-carcinogenic. 
Azo-compounds are responsible for the appearance of liver tumors (hepatomas and 
colangiomas); they are metabolized to active compounds after the introduction of a 
hydroxyl group and conjugation with sulfuric acid. As well as being activated by the body, 
azo-compounds can also be inactivated through protective synthesis (e.g., conjugation 
with glucuronic acid, reduction and cleavage of azo-bond).  
Group B vitamins, especially riboflavin, and substances which act as inducers of enzymes 
in the microsomal system (involved in inactivating the enzyme), can protect from the 
appearance of liver tumors [8].  
Nitrous oxide compounds, azoalkanes, carbamates and ethionine  
Nitrous compounds, azoalkanes, carbamates and ethionine are defined as non 
spontaneous alkylating compounds, because they acquire this capacity after metabolic 
activation. 
Nitrous oxide compounds are divided into nitrosamines, compounds in which the N-NO 
group is linked directly to two alkyl radicals, and nitrosamides, compounds in which the 
two amino-nitrogen valences are saturated by an alkyl and a non-alkyl radical, 
respectively. 
Examples of nitrosamines are dimethylnitrosamine and diethylnitrosamine (Figure 9). 
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Dimethylnitrosamine                 Diethylnitrosamine 
Figure 9. Examples of nitrosamines 
Examples of nitrosamides are methylnitrosurea and methylnitrosoguanidine (Figure 10). 
 
 
 
     Methylnitrosurea            Methylnitrosoguanidine 
Figure 10. Examples of nitrosamides 
 
Because nitrosamides undergo metabolic activation with formation of azoalkanes 
without enzyme intermediation, they are also considered direct carcinogens. 
Nitrosamides are, however, also rapidly inactivated by enzyme systems that provide for 
the removal of the nitrous group.   
Azoalkanes are divided into properly said azoalkanes with general structure of alkyl-N=N-
alkyl, hydroazoalkanes with general structure-alkyl-NH-NH-alkyl and azoxyalkanes with 
general structure of alkyl-N=NO=alkyl. Among hydrazines, the hydrazide of isonicotinic 
acid or isoniazid - used with great success in the treatment of tuberculosis - is oncogenic 
for some strains of mice, in which it induces the appearance of lung cancer.  
Among the carbamates, urethane (ethyl carbamate) with the formula C2H5-O-CO-NH2, 
used for many years as an anesthetic, analgesic and sedative, is considered a complete 
carcinogen for some particular organs such as liver, lung and mammary gland; it is an 
initiating agent for the skin and promotes the induction of leukemia by radiation. It acts 
only after metabolic activation to N-hydroxyurethane, which is subsequently esterified. 
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Finally, ethionine, the ethoxide derivative of methionine, induces the formation of 
hepatic hyperplastic nodules, which degenerate into proper cancers. Enzymatic 
activation forms its active derivative, S-adenosylethionine, which alkylates DNA at the 
site of guanine [8]. 
Natural substances: aflatoxins, cicasine and safrol  
Aflatoxins are substances produced by the fungus Aspergillus flavus, which contaminate 
foodstuffs like cereals, bread, and wine, stored in hot and humid environments. 
Aflatoxins are metabolized in cells to epoxides that can bind to DNA by forming an 
adduct or can be activated by the epoxide hydroxylase enzyme and then conjugated with 
glutathione. In association with hepatitis viruses they can cause liver tumors. 
Cicasine, contained in the Cycas nut, whose flour is used by some populations in the Far 
East, induces liver, kidney and digestive tract tumors in some rodents. Chemically, 
cicasine is the β-glucoside of methyl-azoxy-methanol and, thanks to a specific β-
glucosidase synthesized by intestinal bacteria, the azoxy-methanol, a carcinogenic 
azoalkane, is released.   
Safrol is a component of sassafras oil, little used industrially in the cosmetics and food 
industries. After hydroxylation, which leads to the formation of the carcinogenic 
intermediate hydroxysafrol, and esterification with acetic acid or sulfuric acid, it will form 
the active compound acetoxy-safrol, which easily generates adducts with the O6 of 
guanine. In rats, this compound induces the appearance of hepatomas [8].  
2.3.3 EPIGENETIC CANCEROGENS 
Epigenetic (or non-genotoxic) carcinogens do not act on DNA and therefore are not 
capable of inducing mutations. They generate malignancies following functional 
dysregulation of genes without structural alterations to them. 
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Among epigenetic carcinogens is asbestos, a material widely used in construction and 
various other industries; it includes a family of fibrous silicates, very similar to each other, 
classified as "serpentine" or "amphibole". Serpentine are flexible fibers, while the 
amphiboles, mainly represented by crocidolite and amosite, are stiff narrow rods. 
Deposition of asbestos fibers in lungs depends on their diameter and their length; thick 
fibers (3-10 µm) stop in the upper respiratory tract and are responsible for pulmonary 
fibrosis, while thin ones (< 0.25 µm) are deposited in the terminal airways and alveoli and 
are responsible for tumors. The tumor characteristically associated with exposure to 
asbestos fibers is malignant mesothelioma of pleural and peritoneal cavities. This cancer 
is extremely rare in the general population but it was observed in 2-3% of workers heavily 
exposed to asbestos. These fibers are inhaled during work in mines or manufacture and 
installation of asbestos insulation material, near asbestos factories and in contaminated 
air in buildings under repair or demolition, and from the clothes of the workers handling 
this material. 
The latency period, i.e. the interval between exposure and the appearance of the tumor, 
is of about 20 years but can also be double. It is likely that tumors reflect close contact 
between peritoneal and pleural membranes and asbestos fibers, transported to them by 
the lymph vessels; however, the pathogenesis of mesothelioma associated with asbestos 
is currently unknown. 
Due to the strong synergism with smoking, asbestos is responsible for increasing 
incidence of lung tumors and perhaps even gastrointestinal and laryngeal cancers [7].  
2.3.4 OTHER CARCINOGENIC COMPOUNDS 
Halogenated Hydrocarbons 
This class of compounds includes industrially produced solvents, resins, insecticides, 
pesticides and plastics. Consequently, their use has increased considerably over time.  
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Dichloro-diphenyl-trichloroethane (DDT, Figure 11) - an insecticide used ubiquitously for 
many years, thanks to which malaria has been eradicated in many parts of the world - is 
considered only a potential carcinogen because there are no significant results of 
epidemiological investigations, even if it was proved to induce liver tumors in mice and 
rats. One of its derivatives - 2,2-bis (p-chlorophenyl) ethylene - seems to be endowed with 
greater oncogenic power.  
In terms of cancer generation in humans, Chlorophenols, which are used as herbicides, 
insecticides and exfoliants, and some compounds that are associated with them such as 
tetrachloro-dibenzodioxin (TCDD) are certainly more dangerous than DDT. These 
compounds seem to be responsible for cancer of the lung, liver and other organs of the 
respiratory system. 
Chlorobiphenyls are another class of halogenated hydrocarbons toxic to humans and 
carcinogenic to rats and mice. 
Vinyl chloride (CH2=CHCl), the monomer used in the industrial production of many 
polymers (polyvinylchlorides or PVCs), is responsible for human hepatic angiosarcoma. 
It represents the pro-carcinogenic compound, which is metabolically activated to the 
active carcinogen (an epoxide).  
Finally, carbon tetrachloride (CCl4) is both steatogenous and hepato-carcenogenous [8]. 
 
 
 
Figure 11. DDT 
Various organic compounds 
The number of synthetic organic compounds, blamed as carcinogenic, is in constant 
growth, as shown by tests devised and carried out in animals. Among these are the drugs: 
CCl3
Cl Cl
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chloramphenicol; phenacetin, widely used for some considerable time as an analgesic; 4-
quinolone oxide, a highly bactericidal, but equally carcinogenic and mutagenic 
compound; and nitrofurantoin, an antibacterial and antiparasite drug, used as 
disinfectant of the urinary tract. Among the herbicides and pesticides assayed is 
aminotriazole, responsible for professional cancers, and thioacetamide. The study of 
some of the various substances assayed for oncological activity has proved to be 
extremely useful in clarifying some phenomena of metabolic activation [8]. 
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3. HOW ANTITUMOR DRUGS WORK 
 
As tumor cells proliferate unabated, the first aim of researchers was to find compounds 
able to stop the uncontrolled growth of tumor mass. Drugs used in conventional cancer 
therapy are cytotoxic or antiproliferative agents which can be grouped into different 
classes, according to their mechanism of action. They are mainly genotoxic agents that, 
in different ways, interfere with the normal functions of DNA.  
Conventional targets of cytotoxic therapy are the fundamental processes involved in cell 
proliferation, i.e. the functions of DNA and cell division. 
1. Drugs, which interfere with the functions of DNA, are agents causing direct damage 
to DNA (genotoxic agents) through the formation either of irreversible chemical 
bonds or complexes with different stability. These processes alter the conformation 
of the double helix and, consequently, its functionality. Other compounds induce 
indirect damage to DNA by inhibiting biosynthesis of nucleic acids (i.e. 
antimetabolites). 
2. Drugs interfering with cell division are generally inhibitors of mitosis, which affect 
microtubule dynamics with consequent stabilization or inhibition of tubulin 
polymerization, and topoisomerases inhibitors.  
Although the cellular targets of cytotoxic agents in clinical use cannot be considered 
tumor-specific, there is a basis of specificity that justifies their variable efficacy in 
different tumor types. Despite partial specificity, there are two main limitations of 
cytotoxic agents: lack of sufficient selectivity for tumor cells, which is responsible for high 
toxicity - particularly in rapid growth tissues, such as sex glands, hematopoietic tissue 
and mucous membranes (e.g. intestinal) - and phenomenon of resistance to most of 
these drugs, especially in solid tumors. Being also equipped with a powerful 
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immunosuppressive action, these drugs decrease the body's endogenous defense 
capacities and expose the patient to a greater risk of contracting diseases of an infectious 
nature.  
Many preclinical studies on cellular models have shown that the main way in which anti-
tumor drugs kill cancer cells sensitive to treatment, regardless of their chemical structure 
and/or mechanism of action is the activation of programmed cell death or apoptosis. This 
process is finely regulated from a genetic point of view and involves the action of several 
gene products with pro- and anti-apoptotic functions. Alterations involving the 
regulation of this process may cause varying degree of intrinsic resistance, typical of 
most solid tumors.  
Recent acquisitions in terms of molecular characterization of alterations expressed in 
cancer cells have led to the development of new agents and therapeutic approaches 
based on specific cellular targets. The majority of drugs currently used in clinical therapy 
acts on targets associated with cell proliferation and promoting apoptosis [5]. 
The main classes of drugs showing pro-apoptotic effects are: 
 alkylating agents - a chemically and pharmacologically heterogeneous group used to 
treat different types of cancer, which alkylate nucleophilic sites of cellular 
macromolecules, particularly DNA. The consequence of DNA alkylation is the 
formation of inter- and intra-filament cross-links. Clinically, the most effective drugs 
in this class have either a functional bis(chloroethyl)ethylamino- or ethylenimino-  or 
a nitrous-ureic group in their structure. General mechanism of action includes either 
intra-molecular cyclization to form the aziridinium ion (for those compounds having 
a bis(chloroethyl)aminino or ethylenimino functional group) or the formation of a 
vinyl carbo-cation (for those compounds having a nitrous-ureic functional group); in 
both cases a transfer of an alkyl group to a cellular constituent occurs. The main site 
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for the alkylation of DNA is the N7 position of guanine, although other positions may 
be alkylated, as well as other nitrogenous bases and oxygens of the phosphate group 
(Figure 12). This alkylation can change the keto-enol equilibrium and determine 
aberrant codification known as "miscoding”, favoring a coupling of the guanine with 
thymine instead of cytosine.   
 
 
 
 
 
Figure 12. The main targets of alkylating agents in the guanidine core 
 
Although not considered cycle-specific drugs, alkylating agents seem to be more 
effective in G1 or S phases of the cell cycle (Figure 1) and in rapidly proliferating tissues; 
cell can repair damage if endo-and exo-nuclease enzymes, respectively, cut and remove 
the damaged nucleic acid strand [4];  
 topoisomerase inhibitors which induce DNA double strand breaks on binding site with 
proteins (chap. 5); 
 antimetabolites which are compounds with similar structure to essential metabolites 
for the synthesis of DNA and RNA. Since they are substrates and may inhibit specific 
enzymes, the main possible consequences for the cell are the incorrect incorporation 
of aberrant metabolite, block of crucial enzymatic systems, synthesis of metabolically 
inactive compounds;   
  antimitotic drugs, which interfere with cell mitosis and, in particular, with the 
formation/disruption of the mitotic spindle. During mitosis there is polymerization of 
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tubulin, a protein which forms the mitotic spindle. The anti-mitotic compounds 
interfere with this process either by depolarizing microtubules or by leading to the 
formation of other structures different from the mitotic spindle. Under these 
conditions the chromosomes cannot separate properly leading to cell death;  
 intercalating agents, which insert their planar portion between two complementary 
base pairs of the DNA double helix, deforming it and causing it to unwind (see also 
chap. 4.1); 
 groove binders, i.e. chemical compounds containing a side chain, generally 
oligopeptidic, which can be inserted into either the major or minor groove of DNA (see 
also chap. 4.2 and 4.3); 
 strand breakers, which generate radical species that react with the sugar portion of 
DNA, resulting in the breakage of the polynucleotide filament. 
Of all the classes of compounds mentioned here, only the alkylating agents, intercalating 
agents, groove binders, and strand breakers act by interacting directly with DNA. 
Intercalators and groove binders bind to DNA through non-covalent bonds and therefore 
in a reversible manner, while, by contrast, alkylating agents and strand breakers act as 
irreversible inhibitors [5, 9]. 
Anyway, according to their mechanism of action, anticancer drugs were divided into two 
main groups including those which hinder cell division and those which interfere with the 
function of DNA (Figure 13). 
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Figure 13. Schematic summary of different mechanisms of action of anticancer 
agents 
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4. HETEROCYCLIC DERIVATIVES WITH 
INTERCALATING ACTIVITY 
 
In drug-biological target interactions, weak links are much more common than covalent 
bonds because molecules that bind to their receptors through weak bonds are generally 
more selective than those bound by strong bonds. 
This depends on the fact that weak links require perfect adaptation of the drug to the 
receptor site to make an interaction and only a few types of receptors are likely to be able 
to adapt so precisely to a particular drug structure.  For this reason, it has been suggested 
that to design a drug with short duration of action (and therefore lower toxicity) and with 
high selectivity for a particular target, it is appropriate to choose molecules, which are 
not highly reactive and capable of forming weak bonds [4].  
When considering DNA as a biological target and its possible interactions with small 
molecules, often natural or naturally derived, it is usual to classify these interactions 
under three different headings:  
1. Intercalation 
2. Minor groove binding 
3. Major groove binding 
 
4.1 INTERCALATION 
 
Intercalation (Figure 14) is a non-covalent interaction by which a molecule, featuring a 
planar structure, is inserted between the base pairs of DNA perpendicularly to the axis of 
the double helix, causing a vertical separation of base pairs (bp) with deformation and 
elongation of the sugar-phosphate backbone [10]. The main force which occurs in the 
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formation of the complex between an intercalator and DNA is a π stacking (or change-
transfer) interaction due to the heterocyclic nature of the intercalator, which is 
characterized by high electronic dispersion and, consequently, high polarizability; then, 
this interaction is further stabilized by hydrogen bonds and electrostatic forces [11, 12]. The 
majority of natural products that interact with DNA via intercalation (Table 3 and Figure 
18A), also mediate these interactions through additional groove bindings which direct 
them to specific sequences of bases, giving the bond more selectivity, affinity, and 
temporal stability. Similarly, natural products that bind to DNA through minor groove 
binding or major groove binding are stabilized by intercalation too, due to chromophore 
or quinone moieties characterizing the chemical structure of the molecule (see also 
chapter 4.2). 
Many intercalating drugs show common structural features:   
 an aromatic or heteroaromatic planar polycyclic structure, which is responsible for 
the formation of the molecular complex with DNA;  
 groups/side chains, often alkyl, that allow intercalation within one or both of the 
grooves of the double helix of DNA and stabilize the complex as described above.  
Although they may seem deceptively simple, the structural characteristics that motivate 
these activities are very complex and were the subject of deep studies. Studies on some 
intercalating agents, such as anthracyclines, demonstrated that intercalation seems to 
occur preferentially towards an alternating purine-pyrimidine site, perhaps with weak 
selectivity for 5'-CG to 5'-TA. Intercalator’s preference of the purine-pyrimidine base pair, 
rather than the pyrimidine-pyrimidine one, can be explained considering bond strength, 
which is weaker in the former example than in the latter. To compensate the high 
stability of π stacking bond and electrostatic interactions between intercalator and DNA, 
the latter responds with a distortion of its double helix and breakage of existing bonds 
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between parallel pair of nitrogenous bases. The result is the extension and subsequent 
unrolling of the sugar-phosphate backbone. So, intercalating agents do not break 
hydrogen bonds between the base pairs A-T and C-G, but they destroy the regularity of 
the polynucleotide helical structure determining physical distortion of the sugar-
phosphate backbone. As direct consequence, they interfere with the action of enzymes 
which bind to DNA, such as DNA-topoisomerases, altering the degree of super-coiling of 
the DNA and the DNA-polymerase, which catalyze the elongation of DNA chain in the 5'-
3'-direction [11, 13]. By virtue of the close correlation between intercalation and mutagenic 
potential and the action mechanism of heterocyclic derivatives, their use in anticancer 
therapy was suggested. Their interference against topoisomerases is particularly 
significant, in view of their essential role in the processes of replication and transcription, 
expressed through topological changes in the DNA double helix. In fact, topoisomerases 
intervene by cutting and re-joining filaments to adjust positive and negative super-
coiling (i.e. the degree of winding of the double helix of DNA) that is determined, for 
example, above and below the polymerase in action.  
At present, it is thought that intercalation is only the first stage of a series of events, 
which cause DNA damage through other mechanisms. This hypothesis is confirmed by 
the fact that many intercalating antitumor agents, such as anthracyclines, acridines and 
the actinomycins also target topoisomerase II [13] (see also chap. 6). These drugs 
probably bind to the enzyme-DNA complex constituting the "cleavable complex" which 
determines the fragmentation of proteins associated with DNA. This interaction can be 
enhanced by the presence of polar groups or charges that may favor electrostatic 
attraction to the phosphate groups [2, 14]. By contrast, electrostatic interaction with the 
outer part of the nucleotide may be promoted by the presence of a metal. Literature 
reports that metal complexes, for example ruthenium or copper, with planar heterocyclic 
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ligands, are effective DNA-intercalator compounds and that these complexes are often 
more active than the corresponding isolated binders [15].  
This means that the design of cytotoxic compounds can follow different approaches, 
ranging from the synthesis of planar compounds to the synthesis of metal complexes 
with planar ligands and ending with the synthesis of possible coordinating agents, i.e. 
structures capable of forming complexes with metals present in intracellular 
environment. Literature is full of examples of compounds with planar DNA-intercalating 
activity. Many research groups have directed for years their inquiries to interactions 
between the planar structure of polycondensed heterocyclic compounds and biologically 
interesting molecules in order to assess their possible activity and provide an 
interpretation at molecular level of the effect of such structures on macromolecules. The 
main drugs currently used for treatment of tumors, such as mitoxantrone (Figure 15) and 
doxorubicin, have poly-heterocyclic structure and their mechanism of action also 
provides inhibition of topoisomerase II [16], in addition to classical intercalation. 
Equally interesting are the results of a study conducted on series of acridones, acridines, 
and xanthones, which demonstrated their ability to intercalate between base pairs of 
DNA and interact with topoisomerase II by carrying out not only an antitumor, but also 
anti-herpes, function [17]. Ethidium bromide too, commonly used in the electrophoretic 
technique for marking nucleic acids, is known to be an intercalating agent.  
Therefore, synthesis of new polycyclic compounds continues to be a field of great 
interest in medicinal chemistry [11].   
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                      Figure 14. Intercalation                               Figure 15. Mitoxantrone 
 
4.2 MINOR GROOVE BINDING 
 
Although not yet introduced into clinical practice, molecules capable of mediating minor 
groove bindings (Figure 18B and Table 3) represent an interesting example of structural 
design for new anticancer drugs.  
In fact, as these compounds interact with both individual base pairs and deoxyribose 
along the floor of the groove, the level of specificity and selectivity in binding with 
biological target is greatly enhanced (Figure 16). Bond strength, which originally was 
thought to be weak, has instead proved to be endowed with great stability, so much that 
minor groove binders expressed greater affinity for DNA than classic intercalators, 
comparable to which of regulatory proteins have.  
Structural characteristics considered critical for small molecule to be capable of 
interacting with DNA through minor groove binding are the groove width, the groove 
depth, the floor functionality, and electrostatic potential. All of them are strictly 
correlated. The groove width varies from 3-4 Å for the AT-rich segments to over 8 Å for 
those rich in GC. The depth is greater for the AT-rich segments than those rich in GC, due 
to the presence of G exocyclic C2-amine, which enables binding to molecules through 
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hydrogen bonds because of its highly nucleophilicity. Unlike intercalation, following 
which compounds induce changes in DNA conformation, minor groove binders are 
themselves characterized by conformational changes but are responsible for minor - or 
not obvious - distortion of the helical structure [11]. 
 
 
 
 
 
 
Figure 16. Minor groove binding 
 
4.3 MAJOR GROOVE BINDING 
 
Molecules, which mediate interactions with DNA via major groove binding (Figure 17), 
have been clinically less exploited than small molecules or natural products that interact 
with the same biological targets through minor groove binding. This may surprise, 
especially considering the fact that major groove of double helix contains a greater 
number of both donor groups of hydrogen bonds and acceptor sites, and for this reason, 
most proteins recognize and contact this DNA surface. It has been suggested that the 
larger groove is, the wider surface and more extensive binding site it provides, although 
less effective than that provided by the minor groove, which is, on the contrary, deep and 
narrow. To date, there are only a few examples of natural products that selectively bind 
to the major groove (Table 3 and Figure 18C). Most of the compounds bind DNA through 
intercalation and then establish further hydrogen bonds with the major groove. Among 
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the examples reported in the table, there are also Ditercalinium and Leinamycin, which 
have a certain degree of specificity in recognizing particular DNA sequences in the major 
groove, even though their binding affinity is mainly provided by intercalation. Moreover, 
most of natural products which mediate major groove binding are also alkylating agents, 
especially at the N7 position of guanine or adenine, following the formation of epoxide or 
aziridine electrophiles [11]. 
 
 
 
 
 
 
Figure 17. Major groove binding 
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Table 3 [11]. Representative Natural Anticancer Products that interact with DNA by 
Intercalation, Minor Groove Binding and Major Groove Binding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ND, not determined W=A or T; S= C or G; a Clinically approved antitumor drugs; b Clinically used as antibody 
conjugate; c Synthetics drug 
INTERCALATION 
Binding compound Selectivity Action 
Daunomycina 5’-WCG Inhibition of topoisomerase II 
Doxorubicina 5’-WCG Inhibition of topoisomerase II 
Aclarubicina 5’-WCG Inhibition of topoisomerase II 
Idarubicina 5’-WCG Inhibition of topoisomerase II 
Epirubicina 5’-WCG Inhibition of topoisomerase II 
Pirarubicina 5’-WCG Inhibition of topoisomerase II 
Valrubicina 5’-WCG Inhibition of topoisomerase II 
Amrubicina 5’-WCG Inhibition of topoisomerase II 
Nogalmycin 5’-TG, 5’-GT Unknown 
Actinomycin Da 5’-PyGCPu Inhibition of topoisomerase II 
Camptothecin ND Inhibition of topoisomerase I 
Topotecana ND Inhibition of topoisomerase I 
Irinotecana ND Inhibition of topoisomerase I 
Rebaccamycin ND Inhibition of topoisomerase I 
Ellipticine GC-rich Inhibition of topoisomerase II 
Podophyllotoxin ND Inhibition of topoisomerase II (?) 
Etoposidea ND Inhibition of topoisomerase II 
Teniposidea ND Inhibition of topoisomerase II 
Elsamicin 5’-PuG Inhibition of topoisomerase II 
Dynemicin 5’-PuPy ds DNA cleavage 
Echinomycin 5’-CG bisintercalation 
Triostin A 5’-CG bisintercalation 
Luzopeptins 5’-CATG bisintercalation 
Sandramycin 5’-CATG bisintercalation 
Quinoxapeptin 5’-AT, 5’-TA bisintercalation 
Thiocoraline none bisintercalation 
Mitoxantronec 5’-PuPy Inhibition of topoisomerase II 
Bisantrenec 5’-PuPy Inhibition of topoisomerase II 
m-AMSAc 5’-PuPy Inhibition of topoisomerase II 
MINOR GROOVE BINDING 
Bleomycina 5’-GC, 5’-GT ds DNA cleavage 
Mitomycina 5’-CG alkylation/crosslinking 
FR66979 5’-CG alkylation/crosslinking 
Mithramycina G-rich RNA sinthesis inhibition 
Duocarmycins 5’-WWWA alkylation 
CC-1065 5’-WWWWA alkylation 
Yatakemycin 5’-WWAWW alkylation 
Neocarzinostatin 5’-GT DNA cleavage 
Calicheamicinsb 5’-TPyPyT ds DNA cleavage 
Retrorsine 5’-CG alkylation/crosslinking 
Anthramycins 5’-PuGPu alkylation 
Saframycins 5’-GGS alkylation 
Ecteinascidin 743 5’-PuGS alkylation 
Isochrysohermidin 5’-CG reversible crosslinking 
Distamycin A/T-rich RNA synthesis inhibition 
Netropsin A/T-rich RNA synthesis inhibition 
MAJOR GROOVE BINDING 
Pluramycins 5’-PyG intercalation/alkylation 
Aflatoxins 5’-GGG intercalation/alkylation 
Azinomycins 5’-GNT, 5’-GNC intercalation (?)/ crosslinking 
Leinamycin ND intercalation/alkylation 
Ditercalinium 5’-CGCG bisintercalation 
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Figure 18 [11]. Structure of selected antitumor natural products that bind DNA: 
A) Intercalation B) Minor groove binding C) Major groove binding 
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5. TOPOISOMERASES 
 
During normal life processes, such as replication, transcription, DNA repair, nucleosomal 
assembly, and chromosome segregation, DNA tends physiologically to change its shape:  
topological changes can affect both winding of the two DNA strands, one around other, 
and supercoiling of double helix around its axis. Supercoiling is regulated by specific class 
of enzymes - DNA topoisomerases - which plays the crucial role of controlling the 
topological state of DNA, maintaining functionality and proper gene expression [18]. Any 
modification of the topology of DNA requires the breakage of at least one of the two 
strands, so that the other can then wind around it. 
Therefore, DNA topoisomerases are ubiquitous enzymes essential for solving these 
complex topological problems of DNA in the above-cited fundamental processes (see 
also chap. 5.2).  
All known DNA topoisomerases possess three characteristics: 
1.  The first one is the ability to break DNA’s phosphodiester skeleton via two successive 
transesterification reactions. During the transient stage of DNA breaking, a covalent 
DNA-protein intermediate forms between hydroxyl group of a tyrosine of the 
enzyme and a phosphate group, at the breaking point of the DNA.  
2. The second feature of this enzymes, after the intermediate topoisomerase-DNA has 
formed, is to allow the broken ends to be separated, thus creating another opening 
for another segment of DNA, either single-stranded in the case of DNA 
topoisomerase I or double-stranded in the case of DNA topoisomerase II.  
3. The third characteristic is to covalently re-weld the two ends of the filaments 
previously cut [5, 19].  
 
 53 
 
Introduction 
5.1 CLASSIFICATION  
 
Since the discovery of the first DNA topoisomerase I in E. coli [20, 21], in 1971, these 
enzymes have been found in all eukaryotic and prokaryotic cells, numerous phages, and 
viruses.  
On the basis of the action mechanism they catalyze, these enzymes are classified in DNA 
topoisomerases types I and II [22].  
On the basis of common enzymatic properties and homology of the primary and structural 
sequence, human DNA topoisomerases I are further grouped into three evolutionarily-
related sub-families, i.e. type IA, IB, and IC DNA topoisomerases. While type IA 
covalently binds to the 5' end of cut strand during catalytic cycle, type IB binds covalently 
to the 3' end.  
Topoisomerases II also fall into two subclasses: IIA and IIB, but only the IIA type is human; 
only recently, type IIB has been discovered in a particular bacterial strain [23]. 
Type I DNA topoisomerases modify DNA topology enabling the passage of an intact 
filament through a momentary breakage, which is generated on the complementary 
spiral, following the formation of a covalent intermediary with nucleic acid; they 
therefore act as monomers and catalyze the breaking in one single filament of DNA to 
allow relaxation of the double helix. The binding energy is stored in the intermediate 
DNA-protein (i.e. the phosphotirosinic bond); this means that the energy released by the 
phosphodiesteric bond cleavage is used to perform the twisting motion of the single 
strand bound to the enzyme to allow this relaxation. Therefore, no energy cofactor is 
necessary for this activity of DNA breakage and reunion, and the bond number changes 
by a single unit [24].  
Type II DNA topoisomerases act as homodimers or heterodimers producing double 
openings in both strands of the double helix. In this case, their catalytic activity requires 
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ATP consumption, which is actually used to introduce conformational changes in the 
enzyme, such as allowing the passage of the intact duplex into which the double-strand 
break is present; the bond number changes by two units. 
As remarked above, in both cases, during the rupture stage of DNA, an intermediate 
covalent DNA-protein is formed at the site of rupture between the hydroxyl group of a 
tyrosine of topoisomerase and a phosphate group of the DNA (Figure 19).  
 
 
 
 
 
 
Figure 19. General reaction catalyzed by DNA Topoisomerases 
 
DNA topoisomerases therefore convert one topological isomer of DNA into another one 
only after either the variation of bond number, in the case of topoisomerase I (Figure 
20A-B), or the decatenation of two concatenated DNA rings (Figure 24), in the case of 
topoisomerase II [24] (see also chap. 5.5). 
 
5.2 MAIN CELLULAR FUNCTIONS OF DNA TOPOISOMERASES 
One of the main functions of topoisomerases is to prevent excess of positive and negative 
DNA supercoils, which may cause either structural or functional alterations in cells.  
Those supercoils, which require the intervention of topoisomerases, are generated 
mainly by numerous processes involving the movement of large macromolecular 
complexes along DNA, like semi-conservative replication, during which positive supercoils 
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are generated ahead of the replication fork, while parental filaments are separated 
behind.  In yeast, for example, topoisomerase I (Top1) is the main responsible factor to 
control supercoiling during these events.  
Transcription can generate too positive supercoils in DNA ahead, and negative behind 
the polymerase: in this case, topoisomerases relax negative supercoils leading to 
accumulation of the positive ones.  
Topoisomerases can act in different ways to control the degree of DNA supercoiling:  
a) eukaryotic topoisomerases I and II and bacterial topoisomerase IV can efficiently 
remove both positive and negative supercoils;  
b) bacterial topoisomerases I and III and eukaryotic topoisomerase III can efficiently 
remove negative supercoils, but not positive ones, unless a single filament DNA 
region is present;  
c) bacterial gyrase and reverse gyrase are unique in their ability to convert positive 
supercoils to negative.  
Moreover, the activity of topoisomerases is required for the occurrence of other 
important cellular events, such as chromosome segregation, chromosome 
condensation/decondensation (especially in topoisomerases II), and maintenance of 
genomic stability [25]. 
 
5.3 DNA TOPOISOMERASE I 
As already discussed in previous chapters, type I DNA topoisomerases perform a single-
strand cut in order to relax supercoiled DNA.  
All enzymes from class Ι fall into three families differing in their mechanism of DNA 
relaxation and prokaryotic/eukaryotic origin [23]. 
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Topoisomerases ΙA: prokaryotic origin, they require magnesium ions and molecules of 
single-stranded DNA for their catalytic activity. The first topoisomerase of this sub-
family - E. Coli - was discovered by Wang in 1971. Except for the reverse gyrase of 
Methanopyrus kandleri, these enzymes are all monomeric; as their activity decreases 
when DNA tends to a relaxed state, they only partially relax negatively wrapped DNA and 
covalently bind to the 5' extremity of the cut strand leaving the free hydroxyl in 3’ [19, 20].  
This family is further divided into four subgroups: 
a. Bacterial Topoisomerases I; 
b. Bacterial Topoisomerases III;  
c. Eukaryotic Topoisomerases III, important in processes of recombination, DNA 
repair, maintaining genomic stability, and  transcription of ribosomal RNA genes. 
Among this subfamily, subtypes IIIα and IIIβ are known. 
d. Reverse gyrase, a non-monomeric enzyme present only in thermophilic and 
hyperthermophilic bacteria (e.g. Methanopyrus kandleri) [22, 23].  
The prototype of this class is represented by the topoisomerase I of E. Coli (known as 
"protein ω"). By X-ray crystallography and nuclear magnetic resonance, it was possible 
to delineate the structure of this protein, which consists of 865 amino acids and is divided 
into three domains:  
1. The N-terminal domain, known as cleavage-strand passage domain, containing 
Tyr 319 of active site, which enables the cutting of one filament and the rotation 
of the other. This domain is part of conserved elements, as it is present in other 
members of this subfamily too.  
2. The second is a domain, which contains three zinc finger motifs binding DNA; 
they are important in the step during which the passage of filament takes place 
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(in other classes, these motives that bind zinc retain the same functions, even if 
they differ in structure and sequence). 
3. The final domain is the C-terminal one, which is rich in basic residues and 
contributes to bonding to the substrate; it also confers more affinity for 
molecules of single-stranded DNA. Other members of subfamily too contain a 
relatively basic non-conserved C-terminal domain which presumably performs 
the same function. 
The mechanism of action, known as enzyme-bridged strand passage, is the same for each 
subgroup. This model theorizes the formation of a kind of gate in the covalent complex 
DNA-enzyme, which opens consequently to conformational changes. In the first phase, 
DNA topoisomerase IA binds to DNA through two domains, which delimit the central 
cavity. During the second phase, the domain containing the catalytic tyrosine, i.e. the N-
terminal domain, cuts single-stranded DNA and therefore the catalytic tyrosine binds to 
the 5' end of cut filament, while the 3' end is non-covalently linked to the other part of 
protein bridge. After trapping the second intact strand in the DNA cavity, which already 
accommodates the cut filament, third stage of re-welding reaction takes place. Fourth 
and final phase is the opening of enzyme and emergence of DNA.  
Therefore, the enzyme promotes relaxation of DNA by controlling the passage of the 
intact strand through the split one [22, 23].  In this manner, enzyme's work allows 
modification of DNA bond number by just one unit per cycle. Although a considerable 
sequence diversity between members of IA subfamily has been observed, some common 
characteristics appear to identify the entire subfamily to which bacterial topoisomerases 
I and III, human topoisomerases IIIα and IIIβ and DNA topoisomerase IA (isolated in 
archaebacteria) belong. 
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Topoisomerases IB: eukaryotic and viral origin, they relax negative and positive 
supercoiled DNA. Unlike ΙA Topoisomerases, IB Topoisomerases require neither 
presence of metallic ions, although small amounts will stimulate its activity, nor stretches 
of single-stranded DNA as a substrate for the reaction, which on the contrary is 
represented by double-stranded DNA. Moreover, unlike IA topoisomerases, which relax 
only negative supercoils (with the exception of eukaryotic topoisomerase IIIα which also 
relaxes positive ones), IB Topoisomerases are able to relax both positive and negative 
supercoils, leading to complete relaxation; the latter covalently bind the cleaved strand 
at its 3' extremity [22, 26]. The enzymes of this family relax DNA by a controlled rotation 
mechanism. According to this model, part of the not covalently bound to the enzyme 
double helix, having 5' hydroxyl position free, and therefore not bound to the catalytic 
site - winds around the intact phosphordiester bond which is located opposite the cutting 
site; this rotation is not free, but controlled by electrostatic interactions between the 
DNA bases and amino acids in the enzyme structure [22, 27]  (see also chap. 5.4.1). 
DNA Topoisomerases IB work with an ATP-independent mechanism: energy required for 
rotation is derived from that stored in the supercoiling. For this reason, relaxation of 
stress in supercoiled double helix occurs via one or more cycles of controlled rotation [27].  
These enzymes are monomeric proteins whose dimensions range between 80 and 135 
kDa; they are very important in processes of transcription and DNA replication as they 
relax the positive supercoiling that accumulates above the replicative fork [23]. The 
prototype of this family is DNA topoisomerase I, found in all eukaryotic cells. This class 
also includes viral topoisomerases 1 such as Poxvirus Topoisomerase of Vaccinia Virus, 
whose presence is essential for the virus in order to begin its replication cycle, and which 
has high amino acid sequence homology and very similar enzymatic properties with the 
human type. There is a third category consisting in prokaryotic topoisomerase V, isolated 
 59 
 
Introduction 
from hyperthermophilic archaea such as Methanopyrus Kandleri, which has catalytic 
activity similar to eukaryotic topoisomerase I DNA and Vaccinia but only slight sequence 
homology with these.  
Various mechanisms of action of topoisomerase IA and IB are shown in figure 20 A-B  
Topoisomerases IC: the only member of this family is Topoisomerase V [23], isolated 
from methanogenic archeabacteria. Initially classified as Topoisomerase IB, it is currently 
regarded as the founder of a new class since when its function as well as its 
topoisomerasic activities of DNA repair was recognized. 
 
 
 
 
 
 
 
 
Figure 20. Proposed mechanisms for type I topoisomerases: A) enzyme-bridged 
strand passage for type IA topoisomerases and B) strand-rotation mechanism for type 
IB topoisomerases 
 
5.3.1 HUMAN TOPOISOMERASI I  
Crystallographic structure for human DNA Topoisomerase I has been solved [26], 
providing important information on the three-dimensional structure of the protein. This 
study showed that the enzyme forms a ring surrounding DNA essentially in "B" 
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conformation. Human topoisomerase I is an enzyme of about 90 kDa and consists of 765 
amino acid residues [23]. Structurally, it is a monomer and presents 4 main domains: the 
N-terminal domain; the central domain (also called core domain, which is further divided 
into three distinct sub-domains); the "linker" domain (the two alpha helices that form a 
coiled-coil domain protein that protrudes from the ring); and the C-terminal domain. 
Those essential for catalytic activity are the core and the C-terminal domains, the latter 
of which contains the catalytic tyrosine, while the other two are not indispensable [19]. 
These various domains are organized into two lobes embracing and blocking the DNA 
duplexes: the upper lobe consists of sub-domains I and II of the core and the lower lobe 
is formed by the core sub-domain III and the C-terminal domain. The NH2-terminal 
domain, consisting of about 200 residues, most of which are disorganized and 
hydrophobic, has the function of localizing the enzyme in the nucleus, having at least four 
nuclear localization motives. Apparently, this same domain is also involved in nucleolar 
localization through interactions with specific proteins [28, 29].  
The form of the enzyme resembles that of a calliper and it can be found wrapped around 
the DNA in two distinct conformations: open and closed. In the compact or closed form, 
enzyme exhibits a central pore of about 15-20 Å (Figure 21) inside which is housed the 
DNA. The pore has positively charged residues on the surface, complementary to the 
negative electrostatic potential on the surface of the double helix. Inside the pore there 
is the catalytic site of topoisomerase Ι, which is a domain highly conserved in all 
eukaryotic topoisomerase and consisting of the tyrosine 723. This residue is responsible 
for nucleophilic attack to the phosphate of DNA and is located, as already said, in the C-
terminal domain. In the active site of the enzyme, there are highly conserved amino acid 
residues: two arginines (488 and 590), an histidine (His 632), and a tyrosine (Tyr 723).  
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Figure 21. Structure of human Top1 in its compact form 
 
All of these residues are positioned around the phosphodiester bond to be broken. As 
already said, breaking of single strand of DNA occurs by nucleophilic attack of the OH 
tyrosine. Surprisingly, there is no amino acid residue close enough to be able to act as a 
base to activate oxygen of tyrosine; probably, pentavalent transition state is stabilized 
both by the two arginine residues through hydrogen bridges and the histidine residue 
which protonates 5' oxygen in the position of exiting group. 
5.3.2 ENZYME MECHANISM OF HUMAN DNA TOPOISOMERASE I 
On the basis of crystallographic studies, it was suggested an hypothesis for the 
mechanism of catalysis by eukaryotic topoisomerase I, known as controlled rotation 
model of DNA (Figure 20B). The model proposes that the 5' end of cut strand rotates 
around uncut filament in a not completely free, but braked, way and therefore controlled 
by interaction with the enzyme itself. In fact, it is possible that DNA interacts through 
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ionic bonds with amino acid residues of helices 5 and 6 of core domain and of two long α-
helices of linker domain.  
Activity of human topoisomerase I involves four steps: 
1. DNA bond: the enzyme in open conformation of its core domain recognizes the 
ribonucleotidic chain (22 pb) and leads to the subsequent formation of the non-
covalent DNA-topoisomerase complex, Top1ccs (Figure 22); this bond is directed 
towards the polynucleotide chain by complementarity between structure and 
superficial electrostatic charge of enzyme, and it culminates in the closure of 
topoisomerase around nucleic acid, so that the subdomains I and III of the core domain 
are touching.  
2. DNA cleavage: the amino acids of active site are located in a position such as to enable 
nucleophilic attack by 723Tyr on phosphodiester bond of the DNA to form a 
phosphotyrosinic bond and constitute the cleavable complex in which enzyme is 
covalently linked to cleaved DNA chain (known as Top1 cleavage complex or Top1cc);  
 
 
 
 
 
 
 
Figure 22. Human Topoisomerase I complex with 22 pb DNA duplex 
 
3. DNA relaxation: the enzyme undergoes a conformational change which allows the 
passage of intact filament through the momentary interruption produced in the other 
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one. Relaxation takes place through one or more cycles of controlled rotation of 
broken strand around the intact one. The internal torque of DNA presumably guides 
the  rotation. 
4. DNA mending: it occurs by transesterification. Hydroxyl in 5’ end of cleaved strand 
attacks phosphate, aligned with the hydroxyl group itself, still bound to enzyme 
tyrosine within the complex Top1-Tyr-DNA. Thus the original phosphodiester bond is 
reconstituted. Finally, the enzyme releases DNA [30-32].  
Under normal conditions, the Top1ccs are transient and not detectable, because DNA re-
joining is energetically more favorable than breaking. However, Top1ccs can accumulate 
in cases in which Top1 is trapped by endogenous alterations in DNA (abasic sites, 
mismatches, adducts, nicks) or by chromatin alterations apoptosis-induced [33].  Under 
normal conditions, at the end of the catalytic cycle, one molecule of DNA is released, 
reducing the number of supercoils. DNA may, however, link to the enzyme and undergo 
an additional catalytic cycle.  
The catalytic action of Topoisomerase Ι does not require the presence of energy in the 
form of ATP. Indeed, the process is fully reversible as the energy of the cleaved 
phosphodiester bond is preserved in the phosphotyrosinic bond of the DNA-enzyme 
covalent complex; rejoining passage of DNA, therefore, takes place thanks only to the 
use of energy stored in the phosphotyrosinic bond.  
During genome replication the function of Topoisomerase I is of paramount importance: 
in its absence, movement of the replicative fork - where the stretch of copied DNA 
assumes a shape of a "Y" - would be blocked by accumulation of torsion in the filament, 
which acts as a mold. Its intervention is also essential in the processes of transcription 
and recombination during mitosis. 
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5.4 TOPOISOMERASE II 
 
Topoisomerase II consists of two or more subunits and catalyzes a process similar to that 
of Topoisomerase I. Its mechanism of action is different from the enzymes of class I: 
Topoisomerase II causes a breakage in both strands, which form a double helix in a 
certain region of DNA, and favors the passage through it of another duplex region. It is 
able to relax both positive and negative supercoils. The shape of Topoisomerase II is 
reminiscent of a pincer (Figure 23).  
 
 
 
 
                                                               
 
     Figure 23. Topoisomerase II 
 
The cutting of the two strands occurs after nucleophilic attack by a pair of tyrosines on 
two phosphodiester bonds facing each other, two transesterification reactions that occur 
in a concerted manner. Tyrosine residues are covalently linked to 5' ends of the split 
strands, freeing hydroxyls in positions 3'. The hydrolysis of ATP induces conformational 
changes in the enzyme resulting in the removal of the 5' end (linked) from the 3' (free), 
opening a gate in the cut double helix. At this point, the enzyme carries an intact double 
strand through the created opening created, which is then re-sealed. Finally, 
phosphodiester bonds re-form by a further transesterification [34], resulting in variation 
of two units in the DNA bond number. The reaction only proceeds in presence of ATP, 
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which is essential to provide necessary energy for the significant conformational changes 
involved in the enzyme’s mechanism of action (Figure 24). 
 
 
 
 
 
Figure 24. Proposed mechanisms for type II topoisomerases 
 
On the basis of structural considerations, Topoisomerases II can be divided into two 
subfamilies [23]: 
1) Topoisomerases IIA. The following enzymes belong to this family:  
a) Eukaryotic topoisomerase II: it is a homodimer present in all eukaryotes. It relaxes 
supercoiled DNA both positively and negatively. It is the only enzyme able to unwind 
by decatenation of the DNA chain and it is, for this reason, essential in chromosomes 
separation. lt also cooperates with Topoisomerase I to relax positive supercoils 
during replication processes. 
b) Topoisomerases IV or bacterial gyrase: this is a heterotetrameric bacterial enzyme, 
which appears to be involved in the process of chromosome separation at the end 
of DNA replication process. It seems to be able to introduce negative supercoils via 
a processive catalytic action through the mechanism of the inversion of the sign. 
2)  Topoisomerases IIB: they were discovered in archeobacteria, in which are 
ubiquitous, and recently identified in some bacteria and algae. This family includes 
Topoisomerase IV (archaeal) and Topoisomerase IIB. Only recently, they were 
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isolated in eukaryotic cells where, although it has been clarified their structural role, 
has not yet been hypothesised their physiological function. 
Table 4. Summary of human topoisomerases 
 
  
DNA 
Topoisomerases 
Type 
DNA 
cleavage 
Structural Role Function 
IIIα IA 
Single  
stranded 
Cleavage of supercoiled  
DNA both - and + 
Replication 
Transcription 
of ribosomal 
RNA genes 
IIIβ IA 
Single  
stranded 
Supercoiled - DNA 
relaxation 
Recombination 
I IB 
Single  
stranded 
Supercoiled  DNA 
relaxation both - and + 
Replication 
Transcription 
Recombination 
IIα IIA 
Double 
stranded 
1) Supercoiled DNA 
relaxation both + and - 
2) Facilitates undoing 
DNA knots or breaking 
the tangled  DNA chain. 
Condensation 
of 
chromosomes 
Segregation of 
chromosomes 
replication 
IIβ IIA 
Double 
stranded 
1) Supercoiled DNA 
relaxation  both + and- 
2) Facilitates undoing 
DNA knots or breaking 
the  tangled  DNA chain 
Not well 
defined 
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6. DNA TOPOISOMERASES AS TARGETS 
FOR ANTICANCER DRUGS 
 
DNA Topoisomerase enzymes are largely characterized by their mechanistic and 
functional aspects. The focus on DNA Topoisomerases in recent years not only derives 
from the fact that these proteins play an important physiological role in many nuclear 
processes (e.g. duplication, transcription and repair of DNA etc.) to maintain the 
topological state of nucleic acid, but also because they are pharmacologically significant, 
as they can be transformed into cellular toxins thanks to the action of a specific group of 
anticancer drugs which inhibit their function [5].    
In human cells the two enzymes are not expressed in the same way: topoisomerase I is 
very abundant in solid tumors (e.g. colon), while topoisomerase II predominates in breast, 
ovaries, and liquid tumors. In either case, the tumor tissues, whose cells proliferate 
actively and rapidly, have a higher concentration of these enzymes compared to healthy 
cells; the possibility of exploiting this enzyme for therapeutic inhibition has prompted 
researchers to develop many drugs with this precise mechanism of action [35, 36]. 
We can therefore say that, at present, topoisomerases have assumed primary 
importance in cancer research and many drugs, which act inhibiting these enzymes, are 
among the most widely used in chemotherapy against human cancers [5].  One of the 
primary goals of biotechnological cancer research is the development of more efficient 
drugs able to overcome drug resistance. 
The anticancer drugs currently known for their anti-topoisomerase activity can be 
divided into two classes, according to their mechanism of action [37]: 
1) Class I drugs or poisons: they stabilize the covalent DNA-topoisomerase I complexes 
by forming a reversible ternary DNA-enzyme-inhibitor complex, which is catalytically 
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inactive, since the re-joining stage of DNA is inhibited [25]. The stabilization of 
covalent topoisomerase-DNA complex is an obstacle for proteins sliding along the 
DNA (helicase, DNA polymerase, RNA polymerase). So, the real damage occurs with 
the collision between complex and replication fork - reversible breaking of a single or 
double strand becomes an irreversible rupture of DNA and apoptosis is thus activated 
[38,39]. Often these drugs are referred to as topoisomerase poisons because they 
transform the enzyme into a potent cellular toxin. The main representative of this 
class is the natural alkaloid camptothecin and its semi-synthetic analogues topotecan 
and irinotecan (see chapter 6.1). Also belonging to the class of poisons are other 
intercalator drugs, such as bleomicine, which do not act directly on topoisomerase, but 
interfere with it by intercalating between the bases of DNA and causing lethal actions 
for the cell (see chapter 4.1). 
2) Class ΙΙ drugs or topoisomerase suppressors: they, without directly interfering with 
the covalent complex, act on the catalytic site of the enzyme, preventing its binding 
to DNA. Their cytotoxicity is explained by the fact that they inhibit relaxation of the 
double helix and thus processes involving DNA, such as replication, are prevented. 
Examples are shikonin and β-lapachone (Figure 25). 
 
 
 
 
Shikonin                                                                             β-lapachone                                            
Figure 25. Examples of topoisomerase suppressors 
The classification of topoisomerase inhibitors most commonly used, however, is based 
on the enzyme target, therefore on the ability to interfere with the action of 
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topoisomerase Ι or topoisomerase II. The compounds which inhibit topoisomerase I act 
primarily during the replicative phase of the cell cycle (S phase), whereas lesions caused 
by the topoisomerase II inhibitors are associated with the RNA transcription phase and 
so take place during most of the cell cycle (phase G2/M). 
 
6.1 DRUGS ACTING ON DNA TOPOISOMERASE I 
Among anticancer drugs targeting topoisomerase I, camptothecin (Figure 26) plays a 
role of primary importance. Camptothecin is an alkaloid extracted from the bark of the 
Camptotheca Acuminata Decne plant - family of the Nyssaceae - whose discovery dates 
back to 1966 when Wall and Wani isolated it for the first time. This plant, native to China 
and Tibet, had been known since ancient times for its antifungal properties and has been 
used as a preservative in many foods.  
 
 
 
 
 
Figure 26. Camptothecin 
 
Studies performed in vivo shown that this drug has potent antitumor activity in several 
human tumors, as it selectively inhibits DNA Topoisomerase I. In the past, Redinbo and 
collaborators[26, 27] proposed a model of interaction whereby Camptothecin, through 
intercalation into the DNA duplex, partially overlaps (with its C7) to the guanine residue 
+1 of the cleaved DNA chain, while the lactone ring and the hydroxyl group linked to the 
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chiral center 20 (S) establish interactions with residues Arg364, Asp533 and Asn722 (Figure 
27). 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. [26] Proposed CPT binding mode 
 
However, the extraction of camptothecin from the plant is difficult, particularly because 
of low yields and low water solubility of the compound. Furthermore, the natural 
product, used in the salt form, after opening of α-hydroxy-lactone ring (ring E) proved to 
be less active and substantially toxic because high concentrations of it in the urine cause 
hemorrhagic cystitis. The acidic environment of urine favors the closure of the lactone 
ring, toxic to the bladder mucosa. Camptothecin (CPT) quickly penetrates cells of 
vertebrates and bombards Top1 after a few minutes of exposure; however, the affinity of 
CPT for Top1cc is low and in biochemical tests concentrations in the order of micromoles 
are necessary to detect ternary complexes. Therefore, it can be concluded that CPT was 
selected in nature on the basis of its selectivity, rather than its strength.  
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The study of the chemical structure of camptothecin, the elucidation of the groups 
relevant to the drug activity and the chemical modification of its structure have led to the 
synthesis of two derivatives with potent antitumor activity [5]. The aim was to improve 
CPT pharmacokinetic (rapid opening of the lactone ring to give an inactive compound 
and poor solubility) and pharmacodynamic profile (enlarging, or even diversifying, the 
range of activities with respect to tumor type).  
Although semisynthetic derivatives [39, 40] developed in the past met the requirements to 
be more potent and more soluble in water than the parent alkaloid, attempts to create 
simpler structures, devoid of the main limitations of camptothecin, proved unsuccessful. 
Even today, the production of many derivatives remains partially dependent on the 
availability of camptothecin, since total chemical synthesis is lengthy and expensive. Also 
the extraction of pure alkaloid from plant creates problems.   
Pharmaceutical research of selective inhibitors for topoisomerase I (Top1) is focused 
mainly on two fronts:  
1. On the one hand trying to obtain CPT Top1 derivatives (Figure 33A) with improved 
solubility and increased activity, defined as less reversibility of the binding of CPT in 
the ternary complex.  
2. On the other hand looking for new non-CPT Top1 molecules which are both active 
and selective for Top1 to possibly remedy the problems presented by CPT. 
Regarding CPT Top1 derivatives [31, 32], firstly, changes were made to the A and B rings 
to solve solubility issue and to the E ring for bond strength and reversibility. Changes to 
the A and B rings in the CPT derivatives led to very promising derivatives; at present, two 
molecules are already available for clinical practice: irinotecan (CPT-11, Camptosar® 
Figure 28), a prodrug which is readily hydrolyzed to its active metabolite SN-38 by 
carboxyl esterase (Figure 28); and topotecan (TPT, Figure 29 Hycamtin®). These 
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derivatives are soluble in water and have two different therapeutic indications: the 
former is currently used in the treatment of ovarian and lung cancer while the latter is 
used in colon cancer. Other derivatives such as 9-nitrocampthotecin, G7147211 
(lurotecan), DX-895lf, BN80915 and ST1481 (gimatecan) are under clinical development. 
Other molecules were developed and at the moment are at various stages of preclinical 
and clinical trials [5, 40, 41]. 
  
 
 
 
                           
                       
                         Figure 28.                                                                   Figure 29. Topotecan  
                                                                
                                                                     SN-38 
              
 Irinotecan 
 
 
Structure-activity relationship studies show that the lactone ring E of the CPTs and the S 
configuration at position 20 are essential for antitumor activity. The stability of the ring 
E is a key factor for the activity, since its hydrolysis at plasma level under physiological 
conditions produces copious amounts of inactive carboxylate derivative with high affinity 
for human serum albumin; although this reaction is an equilibrium, the end result is a 
shortage of active CPTs at the site of action.  
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To improve stability new camptothecins were synthesized including homo-
camptothecins, which possess one more methylene group between the hydroxyl group 
and the carboxylic acid of the lactone ring, which thus are 7-membered lactone rings, and 
5-membered rings of ketone type, so non-hydrolyzable. In addition to increased stability, 
these drugs retained the ability to stabilize the DNA-topoisomerase complex. The 
oxyiminomethyl-gimatecan derivative showed very good antiproliferative activity, 
which probably depends on a greater ability in stabilizing the topoisomerase I-DNA 
complex [42, 5] compared to other camptothecins. 
The development of non-CPT Top1 inhibitors (Figure 30 e Figure 33B) [43, 44] was virtually 
contemporary with the discovery of CPT target. This research started by screening large 
libraries of natural molecules and chemical compounds and led to the discovery of three 
categories of molecules:  
o Indolocarbazoles, now the molecules in the most advanced stage of clinical 
development;  
o Indenoisochinolines; 
o Phenanthridines.  
The existence of inhibitors with very different molecular scaffolds becomes a paradigm 
for considering them together as interfacial inhibitors. This fundamental concept arose 
from the observation that CPT alone does not bind neither topoisomerase I nor DNA, but 
acts by forming a ternary complex with topoisomerase and DNA only when these form 
the "cleavable complex". So, interfacial inhibitors are able to establish a network of 
specific hydrogen bonds with residues of the enzyme and hydrophobic interactions with 
the bases of DNA. This interaction is stereospecific, because only the 20 (S) isomer is 
active. 
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Figure 30. Non-CPT Top1 inhibitors 
 
The stereospecific bond at interface of Top I-DNA interaction stabilizes a normally 
transient complex; the prolonged stabilization of an intermediate induces a series of cell 
signals, which lead to death by apoptosis. Generally, these molecules are classified as 
non-competitive inhibitors of the enzyme as they act only in presence of the 
intermediate enzyme-substrate. Therefore, the activity tests for these molecules do not 
concern dissociation, but stabilization of Top1-DNA complex. 
 
6.2 DRUGS ACTING ON DNA TOPOISOMERASE II  
6.2.1 ANTIBIOTIC WITH ANTITUMOR ACTIVITY 
All clinically useful antibiotics are produced by various strains of mildews of genus 
Streptomyces, and include anthracyclines, actinomycin, and bleomycin. The anthracycline 
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antibiotics were isolated from Streptomyces Peucetius (var. Caesius) and they are among 
the most widely used anti-neoplastic drugs. This category includes doxorubicin (Figure 
33C), daunorubicin (Figure 33C), epirubicin (Figure 33C) and idarubicin. The anthracycline 
daunorubicin was discovered in the 1950s as an extremely potent anticancer drug. It is 
still used today, primarily for the treatment of acute leukemia. Doxorubicin (adriamycin), 
another bacterial toxin, was discovered soon after daunorubicin and is more widely used 
[45]. It is in first line therapy against breast cancers, bone and soft tissue sarcomas, bladder 
cancers, anaplastic thyroid cancer, Hodgkin’s and non-Hodgkin’s lymphomas, and 
multiple myeloma. Epirubicin (4’-epi-doxorubicin), an active isomer of doxorubicin 
(Figure 33C), was developed later (FDA approval in 1999) to limit side effects of 
doxorubicin, maybe due to its faster elimination. Epirubicin is used in breast, esophageal, 
and gastric cancers [46]. 
Their molecular structure consists of a tetracyclic ring joined to an aminosugar. The 
molecular pharmacology and mechanism of action of anthracyclines are complex. In 
addition to their anti-Top2 activity, anthracyclines are potent DNA intercalators, since 
the planar tetracyclic ring is inserted between pairs of adjacent nucleobases, while the 
positive charge of the amino group of the sugar stabilizes the bond by interacting with 
the negative charge of the DNA phosphate (Figure 31).  
DNA intercalation causes the inhibition of several DNA-dependent functions. However, 
the relevant mechanism in the cytotoxic/antitumor activity of intercalating agents is their 
ability to interfere with the function of DNA topoisomerase II. This result in a stabilization 
of the intermediate in the topoisomerase reaction, during which the enzyme is covalently 
linked to the ends of the broken filament. Genotoxic stress caused by persistence of the 
ternary enzyme-DNA-drug complex, in particular the double-strand breaks, is 
recognized as a fatal injury by activating cell death.  
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Figure 31 [5]. Action mechanism of anthracyclines 
 
There are other two known mechanisms whose role in cytotoxicity of anthracyclines 
remains to be defined:  
1. ability to bind to and damage cell membranes by altering permeability especially to 
calcium ion.  
2. production of free radicals and reactive oxygen species through oxidative-reductive 
metabolism of anthrachinolic ring. Free radicals contribute to DNA damage and 
induce oxidation of membrane lipids.    
Alteration of membrane permeability and production of free radicals may be the cause 
of cardiac toxicity characteristic of these drugs [5].  
Among intercalating agents, there are also acridinies derivatives, such as amsacrine 
(mAMSA, Figure 33E) and ellipticinium (Figure 33E). 
6.2.2 DRUGS OF SYNTHETIC ORIGIN THAT ACT ON DNA TOPOISOMERASE II 
The clinical success of anthracyclines has stimulated intense research in the development 
of more effective and less toxic analogues. Among these, the most studied compound is 
mitoxantrone (Figure 33E) which belongs to the chemical class called anthracenediones, 
characterized by the planar structure intercalating devoid of aminosugar. Mitoxantrone 
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has a more limited spectrum of activity compared to doxorubicin, and is used in the 
treatment of breast cancer and lymphoma. The compound has, however, a mile 
tolerability profile (reduced cardiotoxicity) that allows its use in therapy at higher doses. 
Other semi-synthetic drugs acting on topoisomerase II are the epipodophyllotoxins. The 
main representatives of this class are etoposide (Figure 33D) and teniposide (Figure 33D). 
Although they bind to tubulin, they have no effect on the structure and function of the 
microtubules, and have no intercalating activity because at pharmacological 
concentrations the antiproliferative effect is the result of inhibition of topoisomerase II. 
Etoposide is used primarily in the treatment of lymphomas, lung and testicular cancer. 
Teniposide is widely used in the treatment of pediatric leukemia [5, 40]. Among the drugs 
with non-intercalating activity there is also genistein (Figure 32). 
 
 
 
Figure 32. Genistein 
There are also antitopoisomerase medications active on gyrase and bacterial 
topoisomerase IIA: among these, used in antimicrobial therapy, the best known are the 
quinolones, of which the precursor is nalidixic acid. 
Figure 33 published by Pommier [31] shows the main topoisomerase I inhibitors already 
approved or under clinical trial. 
A peculiarity of all inhibitors of DNA topoisomerase is that their action is sequence-
specific. In vitro experiments with purified topoisomerase show particularly clearly how 
drugs belonging to different chemical classes typically stimulate DNA breaks at different 
sites, providing intensity patterns of drug-specific breaks. 
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Figure 33 [31]. Structure of anticancer topoisomerase inhibitors 
A: Top1 inhibitor CPT-likes. B: Some non-CPT-like Top1 inhibitors in clinical trials. C: Anthracyclines. D: 
Demethylepipodophyllotoxin derivatives, including the clinical trial drug F14512. E: Other Top2cc-targeted 
intercalative drugs. F: Three Top2cc-targeted drugs in clinical trials in addition to F14512 shown in panel D. G: 
Top2 catalytic inhibitors. 
 
However, in the nuclear chromatin the situation is more complex, since the accessibility 
of topoisomerase to DNA is strongly limited by the presence of other proteins, especially 
of nucleosomes and H1 histone [47-49]. So, in chromatin of cells in culture, localization of 
DNA breaks, produced by enzyme and stimulated by drugs, is determined by several 
factors, including the drug itself and the local structure of chromatin. 
For all the reasons listed above topoisomerases inhibitors, especially CPT, are also often 
used for studies genetic factors involved in the cell-cycle regulation and DNA repair, in 
response to damage mediated by Top1.  
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6.3 MECHANISMS OF RESISTANCE: RESISTANCE MULTIPLE 
INVOLVES DNA TOPOISOMERASES INHIBITORS 
Intrinsic and acquired mechanisms of resistance include:  
1) expression of membrane proteins involved in transport of drug;  
2) mutations and changes in expression of proteins involved in cell cycle regulation and 
in DNA damage repair; 
3) changes in genetic structure (mutations) and expression of topoisomerases. 
Alterations in expression of membrane proteins are the basis of the phenomenon known 
as phenotype of multiple resistance. In fact cells which show this phenotype have 
multiple resistance towards many drugs having not correlated chemical structure. The 
study of this phenotype has highlighted the involvement of various membrane 
transporters capable of reducing concentration of drugs, before reaching their target, 
through the regulation of their efflux. The best-known transporters are encoded by 
genes MDR-1, MRP and LRP. The product of mdr-1 (multi-drug-resistence-1) is a 
membrane glycoprotein, also known as P-glycoprotein, which functions as a pump able 
to expel drug from cell with energy consumption. More recently, two other transport 
proteins, showing behavior similar to mdr-1, were discovered: MRP (multidrug-
resistance-associated protein) and LRP (lung-resistance protein). MRP is a family of 
membrane proteins with many structural and functional similarities to P-glycoprotein. In 
fact, they possess a domain for binding and hydrolysis of ATP and transmembrane 
domains with structural function. Seven proteins (MRP1-7) form this family of 
transporters and by among which only MRP1, MRP2, and MRP3 are involved in multiple 
resistance phenotype. LRP is localized into the nuclear membrane and is involved in 
expulsion of drug from nucleus - where topoisomerases perform their function - to 
cytoplasm.  
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Mutations and decreased expression of topoisomerase may be responsible for a particular 
type of resistance (atypical MDR phenotype), which involves only drugs that target 
topoisomerases. However, the role of these alterations in the target enzyme in clinical 
resistance remains uncertain, although it is plausible that the phenomenon of resistance 
is complex and involves not only defense mechanisms or alteration of the target cell, but 
also recognition of, and response to, injury (for example, repair capacity and 
susceptibility to apoptosis) [5].  
Cellular resistance to camptothecin and its derivatives also occurs following a 
combination of factors, which reduce formation of the ternary complex CPT-DNA-Top1; 
among these factors repair proteins, especially the tyrosyl-DNA phosphodiesterase 1 
(Tdp1) plays a predominant role. Tdp1 is an exponent of the enzyme phospholipase D 
category, which by acting on DNA-Top1, catalyze hydrolysis of the phosphodiester bond 
between 3' terminal end of DNA strand and tyrosine residue of catalytic site (Tyr 723), via 
a two-step nucleophilic substitution. The enzyme can be considered a modulatory target 
in the activity of Top1 poisons; in fact, its inhibition should lead to an increase in cytotoxic 
activity of these drugs, through failure to inhibit the aforesaid ternary complex. We can 
therefore say that the combined therapy of drugs, which inhibit Top1, and those 
inhibiting Tdp1 can potentially be a very effective synergistic association.  
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DNA topoisomerases (Top) are essential enzymes inducing DNA modification required 
during cellular processes such as replication, transcription, and repair. There are two 
major families of Top: type I (Top1) and type II (Top2) depending on whether they cleave 
only one or two DNA strands. Top1 relaxes supercoiled DNA by forming DNA single-
strand breaks and relegates the broken strand to rapidly restore intact duplex DNA. At 
this stage, the enzyme is particularly vulnerable to a group of anticancer agents, Top1 
poisons, that reversibly trap the Top1-mediated cleavage complex, leading to irreversible 
DNA strand breaks, activation of apoptosis, and cell cycle arrest. Top1 inhibitors are a 
relatively new group of anticancer agents with a wide range of activity in hematological 
and solid tumors. Campthotecin I (CPT, Figure 34) was the first small molecule identified 
as Top1 inhibitor. Efforts to improve its toxicity profile and pharmacokinetics led to the 
development of two clinical water-soluble CPT derivatives, topotecan II (Figure 34) and 
irinotecan, as well as novel compounds currently under clinical evaluation. However, 
CPTs are not ideal drugs as they display a number of limitations, including chemical 
instability and potential induction of cellular resistance. To overcome the main 
drawbacks of CPTs, several chemical classes of not-CPT Top1 poisons were developed as 
promising antitumor drugs, including phenanthridines III and indenoisoquinolines IV 
(Figure 34). 
As part of the program in search for new antiproliferative agents, in the last decades the 
research group, with whom I did my thesis work, studied several polyheterocyclic 
systems and recently directed its attention to a new class of drugs with general formula 
V (Figure 35). 
 
 
 
 83 
 
Introduction to Experimental Section  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Structure of known Top1 Inhibitors 
 
 
 
 
 
 
 
Figure 35. Design of Pyrazoloquinazolines 
 
This class is characterized by a 2(3)-phenylpyrazolo[1,5-a]quinazoline structure, a novel 
scaffold to develop non-CPT agents acting against Top1. 
Actually, the core of V (Figure 35) would mimic the A, B and C rings of IV (Figure 34), 
while the phenyl hanging from the pyrazole portion of V (Figure 35) could mimic the 
substituted D ring of IV (Figure 34). Compounds bearing a phenyl alternatively at 2- or 3- 
position of pyrazolo[1,5-a]quinazoline system were designed. As a protonable chain 
linked at the 5- or 6-position of indenoisoquinoline ring or at the 5-position of the 
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benzophenanthridine system is a common feature of most active derivatives, the 
pyrazoloquinazoline ring was functionalized at the 4- or 5- position with aminoalkyl 
chain. In particular, the effects of various decorations on the Top1 inhibitory activity were 
studied, specifically: 
I. the length of chain; 
II. the nature of the linker between the heteropolycyclic ring and the basic terminal 
group; 
III. the nature of the terminal basic moiety. 
Interestingly, these compounds featuring a basic nitrogen in the side chain could be 
converted in the corresponding salts, thus increasing aqueous solubility that might 
facilitate their formulation. 
In this study, derivatives 36-69 were prepared and evaluated for their ability to inhibit 
Top1 (Table 1), and an advanced docking protocol was employed to rationalize the 
biological results. Table 1 lists the relative potencies of pyrazoloquinazolines 36-69 
toward production of Top1-mediated  DNA cleavage sites and their respective intensity 
in each lane as compared to the positive control lanes containing CPT I or MJ-III-65, 
(Figure 34) at 1 µM. Compounds 36-38 that were synthesized due to their structural 
similarities with the indenoisoquinolines IV, showed null Top1 inhibitory activity. So the 
attention was turned to 2-phenylpyrazoloquinazolines bearing different protonable 
chain at the 5-position (39-43). These substitution patterns did not produce favorable 
effects on biological activity, too. Only derivatives 39 and 40 showed a scares activity as 
Top1 inhibitors. Then, compounds 44-69 were designed by shifting the pendant phenyl 
from position 2 to 3 and slightly expanding the variability of chain in 5 with respect to 36-
43. The presence of the 3-phenyl produced a general improvement in the biological 
activity (44-69, Table 5), suggesting a specific arrangement of the molecule favorable for 
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Top1 inhibition. Initially, an electron-donating OCH3 was inserted at p-position of the 3-
phenyl (44-50) due to the well-known beneficial effect of this substituent on potency of 
Top1 inhibitors, but the presence of this substituent does not particularly favor the 
activity, whatever the nature of chain at 5-position is. Then, variously (CF3, Cl, H) 4’-
substituted compounds 51-69 were developed to expand SARs. An analogous effect to 
4’-OCH3 is produced by a highly electron-withdrawing CF3 substituent (51-57).  
Conversely, the presence of the lipophilic and electron-withdrawing 4’-Cl (58-64) 
determined an enhancement in the biological activity.  
In this subclass, nature of the 5-chain, in terms of type (-O- or -NH-) and length of the 
linker, and terminal nitrogen containing group moderately influence Top1 inhibitory 
activity. The imidazole-containing chain (64) scored the worst results, while the best 
activity was obtained with dimethylaminoethylamino, dimethylaminopropylamino, 
diethylaminoethylamino chains (61-63) An analogous trend was observed when 4’-
position is unsubstituted (65-69); the presence of a terminal imidazole nucleus results to 
be detrimental for the activity, whereas a 5-dimethylaminoethoxy moiety confers to 65 
an increase in Top1 inhibition. 
Figure 70 displays the top1-mediated DNA cleavage patterns for compounds 37, 53, 59 
and 61-64, selected as representative of the whole series, along with those resulting from 
I and the indenoisoquinoline MJ-III-65 (Figure 34). It should be observed that compounds 
61-63, differently from poorly active 37, 53, 59, and 64, showed cleavage sites that are 
common to CPT and MJ-III-65.  
These biological results and an advanced docking protocol, employed to rationalize 
these ones, were performed to link the Top1 inhibitory activity and relative potencies of 
these pyrazoloquinazolines. 
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Table 5. Topoisomerase I Inhibitory Activities of 36-69 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a A, (CH2)CH2N(CH3)2; B, (CH2)3N(CH3)2; C, (CH2)3-1-imidazolyl; D, O(CH2)2N(CH3)2; E, O(CH2)2N(C2H5)2; F, O(CH2)3N(CH3)2; 
G, NH(CH2)2N(CH3)2; H, NH(CH2)2N(C2H5)2; I, NH(CH2)3N(CH3)2; J, NH(CH2)3-1-imidazolyl; The activity of the compounds to 
produce Top1-mediated DNA cleavage was expressed semi-quantitatively as follows: 0, not active; 0/+, trace of activity; 
+, weak activity; ++, moderate activity; +++, strong activity; ++++, activity equivalent to 1 µM I or MJ-III-65 (Figure 34). 
no. phenyl position Ra X Top1 inhibition 
36  A  0/+ 
37  B  0 
38  C  0 
39 2 D H 0/+ 
40 2 E H 0/+ 
41 2 F H 0 
42 2 H H 0 
43 2 J H 0 
44 3 D OCH3 + 
45 3 E OCH3 0/+ 
46 3 F OCH3 0/+ 
47 3 G OCH3 + 
48 3 H OCH3 0/+ 
49 3 I OCH3 0/+ 
50 3 J OCH3 0 
51 3 D CF3 0/+ 
52 3 E CF3 0 
53 3 F CF3 0 
54 3 G CF3 + 
55 3 H CF3 0/+ 
56 3 I CF3 0/+ 
57 3 J CF3 0 
58 3 D Cl + 
59 3 E Cl 0/+ 
60 3 F Cl + 
61 3 G Cl ++ 
62 3 H Cl ++ 
63 3 I Cl ++ 
64 3 J Cl 0 
65 3 D H ++ 
66 3 E H + 
67 3 F H + 
68 3 H H + 
69 3 J H 0/+ 
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Figure 70. Top1-mediated DNA cleavage induced by compounds 59, 61, 63, 62, 64, 37 
and 53. Lane 1, DNA alone; lane 2, Top1 alone; lane 3, CPT I, 1 µM; lane 4, 
indenoisoquinoline MJ-III-65, 1 µM; lane 5-25, 59, 61, 63, 62, 64, 37, and 53 at 1, 10, 100 
µM, respectively, from left to right. Numbers and arrows on the left indicate arbitrary 
cleavage site positions. 
 
Have been highlighted many similarities of interactions established between DNA-Top1, 
respectively, with topotecan and pirazoloquinazoline compounds; among these ones, 
61-63 display the most interesting pharmacological profile. According to docking results 
(Figure 71), the 3-phenyl establish well-orientated parallel-displaced specific interactions 
with DNA cleavage site (-1A and +1C), which should be lost when phenyl is moved to 
position 2 (36-43). Moreover, in the 3-phenyl compounds enhancement of ligand-target 
charge-transfer interaction, through the introduction of 4’-Cl (58-64), results in higher 
inhibitory potencies - if compared to the unsubstituted 65-69 - because Cl seems to 
perfectly fit in the crevice formed by the -1A and +1C residues of the non-scissile strand. 
Conversely, bulkier substituents in the same position (p-OCH3 and p-CF3) decrease the 
Top1 inhibitory potency (44-57). 
The dialkylaminoalkylamino chain extends outside the double-helix DNA toward a rather 
shallow protein pocket where the exocyclic NH group can donate a H-bond to adjacent 
water molecule. Conversely, compounds bearing exocyclic ether oxygen (58-60) have a 
lower Top1 inhibition rate, maybe for the loss of this water-mediated interaction. Length 
of the aminoalkyl chain and nature of the terminal alkyl site poorly influence the Top1 
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inhibitory potency, except for imidazole, which lowers or removes the Top1 inhibitory 
activity due to the loss of the ionic interaction. 
 
  
 
 
 
 
 
Figure 71. Binging mode of 61 (yellow sticks) at the Top1 (green cartoons) DNA (gray) 
cleavage site. Residues important for ligand binding are highlighted as sticks. H-bond 
are dashed black lines 
 
Encouraging by these interesting results, the aim of this thesis work was to exploit a 
further polyheterocyclic system to develop novel agents able to inhibit the action of 
topoisomerase I. In this vein, a series of 6H-indazolo[2,3-a]quinazoline derivatives of 
general formula VI (Figure 72) were synthesized, bearing different combinations of 
substituents R1 and R2 and different protonable side chains at the 5-position. 
 
 
 
 
 
 
 
 
 
 
 
Figure 72. Indazoloquinazolines 
These new compounds retain the quinazoline structure of derivatives from series V 
(Figure 35). On the contrary, the pyrazole moiety was replaced with an indazole one. In 
N
N
N
A B
C
D
X
VI
(CH2)n N
R1
R2
80-83
X= -NH-, -O-
n= 2, 3
R1, R2= -CH3, -CH2CH3
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this way, the pendant 2(3)-phenyl of compounds 36-69, was replaced by phenyl ring D, 
which is fused with the pyrazole ring to form a tetraheterocyclic structure. The aim is to 
obtain molecules with an improved Top1 inhibitory activity thanks to a reduced flexibility 
of the basic scaffold. The structural analogy with series IV was maintained: likewise to 
pyrazoloquinazolines V (Figure 35), the core of VI (Figure 72) would mimic the A, B, C and 
D rings of indenoisoquinolines IV (Figure 34).  
How already mentioned, a protonable chain linked at the 5- or 6-position of 
indenoisoquinoline ring IV, at the 5-position of the benzophenanthridine system III, as 
well as at the 4- or 5- position of 3-phenyl-pyrazolo[1,5-a]quinazolines V is a common 
feature of the most active derivatives. So, the indazolo[2,3-a]quinazolin-5(6H)-one 
scaffold  was functionalized with basic aminoalkylamino or aminoalkyloxy chains at the 
5-position. We initially take in consideration those side chains that result the most 
promising, in terms of Top1 inhibitory activity, in the pyrazoloquinazolines V, namely the 
dimethylaminoethylamino (80), dimethylaminopropylamino (81), 
diethylaminoethylamino (82) and dimethylaminoethoxy (83) chains [50].  
The key-intermediate for the synthesis of the indazoloquinazoline derivatives 80-83 is 
the indazolo[2,3-a]quinazolin-5(6H)-one 78, whose preparation is outlined in Scheme 1. 
 
 
 
 
 
 
It started by reacting sodium nitrate in 25% aqueous acidic solution HCl at 0° C with the 
commercially available anthranilic acid 72; after about 20 minutes under stirring, this 
NH
N
O
N
78
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diazotization reaction led to the formation of the diazonium salt stable at this 
temperature. In the same reaction environment sodium azide was added dropwise at 0° 
C; this reacted under stirring at room temperature with the intermediate diazonium salt, 
forming the 2-azidobenzoic acid 73, after nearly 18 hours [51]. Then in dry environment, 
under nitrogen atmosphere and at 0° C, 2-azidobenzoic acid 73 reacted with thionyl 
chloride, using anhydrous THF as solvent and heating at reflux. After about 3 hours (TLC 
analysis), 2-azidobenzoyl chloride 74 was formed. Being unstable, it was immediately 
used in the next reaction. The synthetic procedure used was slightly modified from 
literature [52]. 2-Azidobenzoyl chloride 74 and anthranilamide 75 were condensed in the 
presence of triethylamine in anhydrous toluene at room temperature, under continuous 
stirring for 5 hours (TLC analysis). The condensation product 76 underwent a cyclization 
following to dehydration in KOH 1% EtOH solution after 4 hours under continuous 
stirring at room temperature; this reaction involved the formation of the cyclic amide 77. 
Also these synthetic procedures was slightly modified from literature [53]. Finally, the 
indazolo[2,3-a]quinazolin-5(6H)-one scaffold 78 was formed by refluxing 77 in xylene for 
about 19 hours (TLC analysis) under continuous stirring (Scheme 1) [54]. 
The general synthetic procedure for the preparation of 5-substituted-indazolo[2,3-
a]quinazoline derivatives 80-83 is outlined in Schemes 2, 3 and 4.  
Derivatives 80, 81 and 82 were obtained via the transformation of indazolo[2,3-
a]quinazolin-5(6H)-one 78 into the corresponding 5-chloro-derivative 79, according to 
the procedure summarized in Scheme 2. The 5-chloro-substituted derivative 79 was 
obtained by reaction of 78 with benzenephosphonyl dichloride at 180° C for about 4 
hours [50]. 
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SCHEME 1 
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SCHEME 2 
 
    
 
 
The 5-chlorosubstituted derivative 79 was then transformed into the corresponding 
derivatives 80, 81 and 82 by nucleophilic substitution of the chlorine at position 5 with 
the appropriate dialkylaminoalkylamino chain by the use of microwaves. The 
microwave-assisted synthesis is a technique widely used to perform and to accelerate 
organic reactions. This method offers certain advantages, represented by shorter 
reaction time, lower temperature offering potential energetic saving, solvents removal 
allowing a green chemistry and cleaner reactions with minimal discarding and by-
products. In the present procedure, the two reactants underwent to irradiation at 
pressure of 7 bar and 100 W of power for 30 minutes using alumina as solid support and 
EtOH as solvent (Scheme 3). Alumina was also used both as heat dispersant and as 
microwave carrier to make more homogeneous reaction environment [50]. 
Derivative 83 was directly synthesized from the indazolo[2,3-a]quinazolin-5(6H)-one 78 
which was reacted first with sodium hydride in anhydrous DMF and then with the 
hydrochloride salt of 2-chloro-N,N-dimethylethanamine in anhydrous DMF in presence 
of potassium carbonate. After heating the reaction mixture at 155 °C, the compound 83 
was formed (Scheme 4) [50]. 
The reaction yields, chemical-physical constants and spectroscopic characteristics of 
compounds 80-83 are reported in the Experimental Section.  
PhPOCl2
180°C, 4h
78 79
NH
N
O
N
N
N
N
Cl
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SCHEME 3 
 
 
 
 
   
 
 
SCHEME 4 
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MATERIALS E METHODS 
 
Unless otherwise stated, all solvents and reagents used for synthesis were bought 
directly from the suppliers and were used without further purification. The drying agent 
was magnesium sulfate. Evaporation was performed in vacuo (rotary evaporator). Yields 
(%) refer to chromatographically pure and spectroscopically homogeneous compounds 
(1H-NMR). Reactions were monitored by thin layer chromatography (TLC) carried out on 
silicate aluminum foil (MERK 60 F-254, 0.2 mm thickness). Proton magnetic resonance 
spectra of the proton (1H-NMR) were carried out in hexa-deuterated dimethylsolfoxide 
(DMSO-d6) or in deuterated chloroform (CDCl3) using a Bruker 400-MHz spectrometer. 
The presence of exchangeable protons was confirmed by D2O. The assisted microwave 
reactions were carried out in a CEM Discover dedicated oven (CEM). Melting points were 
determined using a Reichert Köfler hot-stage apparatus and are uncorrected. 
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Procedure for the synthesis of 2-azido-benzoic acid 73. 
2g (14.58 mmol) of anthranilic acid 72 was added to a solution of 100.29 ml of water and 
26.08 of concentrated hydrochloric acid (37%) at 0°C. 895 mg (12.98 mmol) of sodium 
nitrite was solubilized in 23.88 ml of water and added drop by drop to the first solution. 
The resulting solution was allowed to stir for about twenty minutes at 0°C. Then a 
solution of 445.6 mg (6.85 mmol) of sodium-azide in 12.11 ml of water was added 
dropwise to the reaction mixture. The mixture was allowed to stir for about 30 minutes 
at 0°C and subsequently at room temperature for 18 hours. The progress of the reaction 
was checked by TLC (Hexane/AcOEt = 3:7).  
At the end a white/pinkish precipitate had formed which was first gathered by vacuum 
filtration and dried. 
2-azido-benzoic acid 73. Yield: 29%, mp: 144°C, let. ref. n° 51: mp ~145°C. 
 
 
Procedure for the synthesis of 2-azido-benzoyl chloride 74. 
439 mg (2.69 mmol) of 2-azidobenzoic acid 73 was solubilized in 20 ml of anhydrous 
tetrahydrofuran (THF) under nitrogen atmosphere at 0°C. Then, 640 mg (0.39 ml, 5.38 
mmol) of thionyl chloride was added dropwise to reaction mixture. The mixture was 
refluxed under stirring for 3 hours. The progress of the reaction was checked by TLC 
(Hexane / AcOEt = 5:5). After cooling, the organic solvent was evaporated to dryness at 
reduced pressure and the oily residue was washed with three portions of anhydrous THF, 
in order to remove the unreacted thionyl chloride. The 2-azidobenzoyl chloride obtained 
was particularly unstable, so it was used without any further purification.  
2-azido-benzoyl chloride 74. Yield: quantitative.  
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Procedure for the synthesis of N-[2-(aminocarbonyl)phenyl]-2-azido-benzamide 76. 
228.26 mg (0.31 ml) of triethylamine was added dropwise to a stirred solution cooled at 
0°C of 2-azidobenzoyl chloride 74 (407 mg, 2.24 mmol) and anthranilamide 75 (305.8 mg, 
2.24 mmol) in 16.65 ml of anhydrous toluene under nitrogen atmosphere. The mixture 
was left under stirring for about 30 minutes at 0°C and subsequently at room temperature 
for 15 hours, until the disappearance of starting compounds (TLC analysis in 
Hexane/AcOEt = 3:7). The suspension was filtered by vacuum filtration; the resulting 
light-brown colored solid residue was taken up with water to eliminate the triethylamine 
hydrochloride formed and under vacuum collected again. The gathered precipitate was 
dried and subsequently purified by crystallization from toluene to obtain the desired 
product as a brown solid. Finally, it was dried. 
N-[2-(aminocarbonyl)phenyl]-2-azido-benzamide 76. Yield: 59%, mp: 173-174°C. 
1H-NMR (400 MHz, DMSO-d6, δ ppm): 7.19-7.21 (m, 1H, Ar-H); 7.32-7.36 (m, 1H, Ar-H); 
7.46-7.48 (m, 1H, Ar-H); 7.54-7.58 (m, 1H, Ar-H); 7.61-7.66 (m, 1H, Ar-H); 7.75-7.79(m, 2H, 
Ar-NH2); 7.82-7.84 (m, 1H, Ar-H); 8.23 (s, 1H, Ar-H); 8.62 (d, 1H, J=12 Hz, Ar-H); 12,30 (s, 
1H, NH exch. with D2O). 
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Procedure for the synthesis of 2-(2-azidophenyl)quinazolin-4(3H)-one 77. 
A solution of KOH 1% / EtOH (50.54 ml) was added to 853 mg (3.03 mmol) of 76 and the 
reaction mixture was allowed to stir for 4h at room temperature until the disappearance 
of the starting material. The progress of the reaction was checked by TLC 
(Hexane/AcOEt=5:5). Then the organic solvent was evaporated to dryness at reduced 
pressure. The resulting solid residue was taken up with water and it was extracted with 
ethyl acetate. After drying with MgSO4, the organic layer was evaporated to dryness and 
obtain the desired product. 
2-(2-azidophenyl)quinazolin-4(3H)-one 77. Yield: 98%, mp: 330°C. 
1H-NMR (400 MHz, DMSO-d6, δ ppm): 7.33-7.37 (m, 1H, Ar-H); 7.48-7.50 (m, 1H, Ar-H); 
7.54-7.58 (m, 1H, Ar-H); 7.62-7.73 (m, 3H, Ar-H); 7.83-7.87 (m, 1H, Ar-H); 8.16-8.18 (m, 1H, 
Ar-H); 12,43 (s, 1H, NH exch. with D2O). 
 
Procedure for the synthesis of indazolo[2,3-a]quinazolin-5(6H)-one 78. 
486 mg (1.85 mmol) of 2-(2-azidophenyl)quinazolin-4(3H)-one 77 was solubilized in 48.6 
ml of xylene and the reaction mixture was heated at reflux and left under stirring for 19 
hours. At the end of the reaction (TLC analysis in Hexane/AcOEt = 5:5) has formed a 
yellow precipitate which was first gathered by vacuum filtration and then dried. 
Indazolo[2,3-a]quinazolin-5(6H)-one 78. Yield: 80%, mp: 187°C. 
1H-NMR (400 MHz, DMSO-d6, δ ppm): 6.97-7.01 (m, 1H, Ar-H); 7.34-7.38 (m, 1H, Ar-H); 
7.56 (d, 1H, J=8.8 Hz, Ar-H); 7.63-7.67 (m, 1H, Ar-H); 7.95-8.02 (m, 2H, Ar-H); 8.26-8.28 
(m, 1H, Ar-H); 8.40 (d, 1H, J=8.4 Hz, Ar-H); 13.21 (s, 1H, NH exch. with D2O). 
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Procedure for the synthesis of 5-chloroH-indazolo[2,3-a]quinolone 79. 
A mixture of indazole[2,3-a]quinazolin-5(6H)-one 78 (174 mg, 0.74 mmol) and 2.22 ml of 
PhPOCl2 was heated at 180 °C for 4 h (TLC analysis in Hexane / AcOEt = 5:5) under stirring 
and with exclusion of moisture. After cooling by addition of ice, the obtained aqueous 
suspension was neutralized with conc. ammonia (30-33%) and the desidered product 5-
chloroH-indazolo[2,3-a]quinolone 79, was isolated directly in a pure state by vacuum 
filtration. 
5-chloroH-indazolo[2,3-a]quinolone 79. Yield: 94%, mp: 197-198°C. 
1H-NMR (400 MHz, CDCl3, δ ppm): 7.37 (t, 1H, J=7.4 Hz, Ar-H); 7.61-7.65 (m, 1H, Ar-H); 
7.78-7.82 (m, 1H, Ar-H); 7.95 (d, 1H, J=8.8 Hz, Ar-H); 8.07-8.12 (m, 1H, Ar-H); 8.29 (d, 1H, 
J=8.4 Hz, Ar-H); 8.43 (d, 1H, J=8.4 Hz, Ar-H); 8.87 (d, 1H, J=8.8 Hz, Ar-H). 
 
General procedure for the synthesis of N-(alkylamino substituted)-indazolo[2,3-
a]quinazolin-5-amine 80, 81 and 82. 
 
A mixture of 5-chloroH-indazolo[2,3-a]quinoline 79 (50 mg, 0.20 mmol), the appropriate 
alkylamine (0.28 mmol) and EtOH (2 ml) was irradiated at 95-100° C, 7 bar, and 100 W for 
30 minutes, using alumina as solid support (TLC analysis in toluene/acetonitrile 5:5 + 0.5 
ml of acetic acid). The crude reaction was filtered on a fluted filter to remove alumina, 
then the solvent was evaporated to dryness at reduced pressure to obtain desired 
product. If alkylamine excess was still, the oily residue was taken up with water and 
extracted with dichloromethane. After drying with MgSO4, the dichloromethane solution 
was evaporated to dryness. The semisolid precipitate was washed with three portions of 
distillate hexane, in order to purify it from chemical dirts. 
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N-(2-(dimethylamino)ethyl)indazolo[2,3-a]quinazolin-5-amine 80. Yield: 49%, mp: 93-
94°C. 
1H-NMR (400 MHz, CDCl3, δ ppm): 2.68 (s, 6H, 2CH3); 3.12 (t, 2H, J=5.2 Hz, CH2); 4.06 (t, 
2H, J=5.4 Hz, CH2); 7.09-7.11 (m, 1H, Ar-H); 7.44-7.48 (m, 1H, Ar-H); 7.62-7.66 (m, 1H, Ar-
H); 7.75 (d, 1H, J=8.8 Hz, Ar-H); 7.89-7.94 (m, 1H, Ar-H); 8.04 (d, 1H, J=8 Hz, Ar-H); 8.29 
(d, 1H, J=8 Hz, Ar-H); 8.71-8.73 (m, 1H, Ar-H). 
N-(3-(dimethylamino)propyl)indazolo[2,3-a]quinazolin-5-amine 81. Yield:41%, mp:103-
104°C. 
1H-NMR (400 MHz, CDCl3, δ ppm): 2.07 (t, 2H, J=5.6 Hz, CH2); 2.53 (s, 6H, 2CH3); 2.78 (t, 
2H, J=5.6 Hz, CH2 ); 3.90-3.94 (m, 2H, CH2CH2CH2); 7.04-7.08 (m, 1H, Ar-H); 7.42-7.46 (m, 
1H, Ar-H); 7.55-7.59 (m, 1H, Ar-H); 7.72 (d, 1H, J=8.8 Hz, Ar-H); 7.86-7.88 (m, 1H, Ar-H); 
7.90-7.93 (m, 1H, Ar-H); 8.06 (d, 1H, J=8.4 Hz, Ar-H); 8.63 (s, 1H, NH exch. with D2O); 8.70 
(d, 1H, J=8 Hz, Ar-H). 
N-(2-(diethylamino)ethyl)indazolo[2,3-a]quinazolin-5-amine 82. Yield: 55%, mp: 98°C. 
1H-NMR (400 MHz, CDCl3, δ ppm): 1.37 (t, 6H, 2CH3); 3.11 (q, 4H, J=7.2 Hz, 2(CH2CH3)); 
3.34 (s, 2H, J=4.9, 2CH2); 4.16 (t, 2H, J=5.2, 2CH2); 7.08-7.10 (m, 1H, Ar-H); 7.44-7.48 (m, 
1H, Ar-H); 7.63-7.67 (m, 1H, Ar-H); 7.75 (d, 1H, J=8.8 Hz, Ar-H ); 7.89-7.94 (m, 1H, Ar-H); 
8.02 (d, 1H, J=8, Ar-H); 8.41 (d, 1H, J=8, Ar-H); 8.70-8.72 (m, 1H, Ar-H). 
 
Procedure for the synthesis of 2-(indazolo[2,3-a]quinazolin-5-yloxy)-N,N-
dimethylethanamine 83. 
 
18.8 mg (0.47 mmol) of sodium hydride (60% dispersion in mineral oil) was added 
portionwise to a solution of indazolo[2,3-a]quinazolin-5(6H)-one 78 (100 mg 0.43 mmol) 
in 7.66 ml of anhydrous DMF, and the mixture was stirred at room temperature for 5h. 
67.70 mg (0.47 mmol) of 2-chloro-N,N-dimethylethanamine hydrochloride was 
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solubilized in 23.88 ml of anhydrous DMF and 64.96 mg (0.47 mmol) of potassium 
carbonate was added afterwards. This second solution was left stirring for 5 hours at 
room temperature and then added drop by drop to the first one. The resulting reaction 
mixture was allowed to stir for about 24h at 155°C (TLC analysis in CHCl3/MeOH = 9:1). 
The organic solvent was evaporated to dryness at reduced pressure. The compound was 
washed with a portion of EtOH in order to remove all anhydrous DMF. The resulting 
residue was taken up with water and extracted with CHCl3. After drying with MgSO4, the 
organic layer was evaporated to dryness at reduced pressure and the solid collected and 
purified with flash chromatography. 
2-(indazolo[2,3-a]quinazolin-5-yloxy)-N,N-dimethylethanamine 83. Yield: 59% mp: 167-
170°C 
1H-NMR (400 MHz, DMSO-d6, δ ppm): 2.27 (s, 6H, 2CH3); 2.70 (t, 2H, J=7.2 Hz, CH2); 4.62 
(t, 2H, J=7.0 Hz, CH2); 7.09-7.13 (m, 1H, Ar-H); 7.37-7.43 (m, 1H, Ar-H); 7.67-7.71 (m, 2H, 
Ar-H); 7.91-7.94 (m, 1H, Ar-H); 8.01-8.05 (m, 1H, Ar-H); 8.31-8.33 (m, 1H, Ar-H); 8.47 (d, 
1H, J=8 Hz, Ar-H). 
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